[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 425
1. Oh SY, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Suh C, Kim HJ: Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. Cancer Sci; 2010 Nov;101(11):2443-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study.
  • Stage IV marginal zone B-cell lymphomas (MZL) are detected in more than 25% of lymphoma patients.
  • In this study, we conducted retrospective analyses of specific cases of stage IV MZL in order to assess their clinical features, as well as the treatments and prognoses of these cases.
  • A total of 94 patients with histological diagnosis of stage IV-MZL from 17 different institutions in Korea were included.
  • Bone-marrow-involved stage IV MZL (BM-MZL) was detected in 33 patients (35.1%).
  • Patients with lymph node involvement in stage IV MZL appeared to have worse prognoses in TTP (P=0.015).
  • Stage IV MZL tend to follow an indolent disease course.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Japanese Cancer Association.
  • (PMID = 20831770.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


2. Belgaumi A, Al-Kofide AA, Khafaga Y, Joseph N, Jamil-Malik R, Siddiqui KS, Sabbah RS: Clinical characteristics and outcome of pediatric patients with stage IV Hodgkin lymphoma. Hematol Oncol Stem Cell Ther; 2009;2(1):278-84
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcome of pediatric patients with stage IV Hodgkin lymphoma.
  • BACKGROUND AND OBJECTIVES: While treatment outcomes for patients with Hodgkin lymphoma (HL) have improved remarkably, patients with disseminated disease still have a poorer outcome.
  • Stage IV HL is often reported with other 'advanced stage' categories, confusing the specific contribution of disease dissemination to the outcome.
  • RESULTS: Stage IV patients (n = 67) had more poor-risk characteristics than patients in stages I-III (n = 300) (B symptoms 86.6% vs. 19.3%, bulky disease 57.6% vs. 45.5% and mediastinal mass 77.6% vs. 29.7%; P < .001 for all characteristics).
  • The liver was the most common extralymphatic site (in 51.5% of patients with stage IV disease.
  • Stage IV patients received chemotherapy (CT) alone (n = 55) or combined modality therapy (CMT) (n = 12).
  • There was a non-significant benefit for CMT (OS = 91.7% v. 77.1%, P = .3; EFS = 70.7% v. 62.7%, P = .3).
  • CONCLUSION: Stage IV disease is associated with poor risk features and confers a worse outcome than stage I-III disease.
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063558.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Oh SY, Ryoo BY, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Kim HJ, Kwon HC, Bang SM, Kim JH, Park J, Lee SS, Kim HY, Park K: Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am J Hematol; 2007 Jun;82(6):446-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nongastric marginal zone B-cell lymphoma: analysis of 247 cases.
  • Nongastric marginal zone B-cell lymphoma (NG-MZL) is a relatively uncommon indolent lymphoma.
  • Ann Arbor stage I/II disease was present in 78% (167 out of 215).
  • Eighty percent (172/215) were in low risk group according to Follicular Lymphoma International Prognostic Index (FLIPI).
  • Complete and partial remissions (CR and PR) were achieved in 140 (92.7%) and 8 (5.3%) of the 151 stage I/II patients.
  • In 38 patients with stage III/IV, CR and PR were achieved in 17 (44.7%) and 11 (26.3%), respectively.
  • Stage III/IV, low hemoglobin, poor performance status, high/high-intermediate IPI, poor risk FLIPI, and nodal MZL were poor prognostic factors for PFS.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17266060.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Arulogun SO, Prince HM, Ng J, Lade S, Ryan GF, Blewitt O, McCormack C: Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood; 2008 Oct 15;112(8):3082-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation.
  • Although mycosis fungoides (MF) is typically an indolent disease, patients with advanced-stage disease (stages IIB-IVB), including Sézary syndrome (SS), often have a poor outcome.
  • A 31-year, retrospective analysis of our cutaneous lymphoma database, of 297 patients with MF and SS, was undertaken to study long-term outcomes and identify clinical predictors of outcome in patients with advanced-stage disease (ASD, n = 92) and large cell transformation (LCT, n = 22).
  • Two-thirds of patients with ASD presented with de novo ASD.
  • Age at initial diagnosis (P = .01), tumor stage (P = .01), and clinical stage (P = .001) were found to be significant predictors of outcome.
  • Patients who presented with de novo ASD demonstrated better outcomes that were not statistically significant than those with a prior diagnosis of early-stage MF (P = .25).
  • Transformation developed in 22 of the 297 MF/SS patients (7.4%), with a transformation rate of only 1.4% in patients with early-stage disease, compared with stage IIB (27%) and stage IV (56%-67%) disease.
  • We confirm that the incidence of LCT is strongly dependent on tumor stage at diagnosis, and we demonstrate a much lower overall risk of LCT than previously reported.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, T-Cell, Cutaneous / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Aged. Cell Transformation, Neoplastic. Disease Progression. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging / methods. Registries. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18647960.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Schneider T, Molnár Z, Deák B, Várady E, Tóth E, Csomor J, Matolcsy A, Lovey J, Lengyel Z, Petri K, Gaudi I, Rosta A: [Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma]. Orv Hetil; 2009 Nov 1;150(44):2019-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma].
  • [Transliterated title] Diffúz nagy B-sejtes lymphomák immunokemoterápiás kezelésével elért eredményeink.
  • Treatment with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been considered as the standard therapy for diffuse large B-cell lymphoma (DLBCL) for more than 20 years.
  • The eligibility criteria included advanced stage (clinical stages III-IV), or large tumour size (>7 cm) and/or symptom B or extranodal manifestation in the case of clinical stages I-II.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunologic Factors / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / immunology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861288.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


6. Maeshima AM, Omatsu M, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y: Diffuse large B-cell lymphoma after transformation from low-grade follicular lymphoma: morphological, immunohistochemical, and FISH analyses. Cancer Sci; 2008 Sep;99(9):1760-8
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma after transformation from low-grade follicular lymphoma: morphological, immunohistochemical, and FISH analyses.
  • Follicular lymphoma (FL) is one of the most common subtypes of non-Hodgkin lymphoma and frequently transforms to diffuse large B-cell lymphoma (DLBCL).
  • Most of the patients (34/43) showed advanced-stage (III or IV) disease initially.
  • Among the DLBCLs, 84% were classified as the germinal center B-cell phenotype (GCB) and 16% as non-GCB in accordance with the criteria of Hans et al. IGH/BCL2 fusion was detected by FISH in 89% of FLs and 82% of DLBCLs.
  • [MeSH-major] Cell Transformation, Neoplastic. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18549405.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


7. Bień E, Stachowicz-Stencel T, Zawitkowska-Klaczyńska J, Adamkiewicz-Drozyńska E, Odój T, Połczyńska K, Mitura-Lesiuk M, Stefanowicz J, Sierota D, Szołkiewicz A, Birkholz D, Hennig M, Kowalczyk JR, Balcerska A: [Clinical characteristics and therapy outcome in children with stage IV Hodgkin's lymphoma--the experience of two oncological centres]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):631-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and therapy outcome in children with stage IV Hodgkin's lymphoma--the experience of two oncological centres].
  • [Transliterated title] Charakterystyka kliniczna i wyniki leczenia dzieci z choroba Hodgkina w IV stadium zaawansowania--doświadczenia dwóch ośrodków onkologicznych.
  • The cure rate in children with Hodgkin's disease (HD), at present time exceeds 90% but the prognosis in stage IV HD is much worse.
  • THE AIM of the study was to analyze the initial symptoms, course and results of oncological therapy in children with stage IV of Hodgkin's disease.
  • MATERIAL AND METHODS: The analyzed group comprised of 15 patients with IV stage HD (M/F: 11/4, mean age: 12 years), treated from January 1993 to March 2005, in two Polish centres of paediatric oncology in Gdansk and Lublin.
  • The diagnosis and therapy were carried out according to the current protocols approved by the Polish Paediatric Leukaemia / Lymphoma Study Group (PPGBCh).
  • The second boy died 12 months after stem cell transplantation because of a second neoplasm--acute myeloblastic leukaemia.
  • CONCLUSION: Chemo- and radiotherapy implemented according to protocols approved by the PPGBCh for children with stage IV HD, result in complete remission in most patients.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317894.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Poland
  •  go-up   go-down


8. Di Bella N, Reynolds C, Faragher D, Muscato J, Boehm KA, Asmar L: An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma. Cancer; 2005 Mar 1;103(5):978-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma.
  • BACKGROUND: In a previous study, the authors demonstrated that the combination of pentostatin (P) and rituximab (R) was well tolerated and was active in patients with low-grade non-Hodgkin lymphoma (NHL).
  • METHODS: Twenty-four previously untreated patients with histologically proven, Stage III or IV, low-grade NHL were registered between April and September, 2002.
  • Eighty-three percent of patients had Stage IV disease, the median patient age was 62 years (range, 4-81 years), and the performance status was 0-2.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Disease-Free Survival. Female. Humans. Lymphoma, Non-Hodgkin. Male. Middle Aged. Mitoxantrone / administration & dosage. Pentostatin / administration & dosage. Pilot Projects. Rituximab. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15672388.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 395575MZO7 / Pentostatin; 4F4X42SYQ6 / Rituximab; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


9. Zajac-Spychała O, Derwich K, Mańkowska M, Konatkowska B, Mańkowski P, Wachowiak J: [Analysis of prognostic factors in children with B-cell non-Hodgkin lymphoma (B-NHL)]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1087-91
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of prognostic factors in children with B-cell non-Hodgkin lymphoma (B-NHL)].
  • INTRODUCTION: The aim of this study was to analyze prognostic factors in patients with diagnosed B-cell non-Hodgkin lymphoma (B-NHL).
  • Median age at diagnosis of both relapsed and non-relapsed children was 8 years.
  • There was no relapse in stage I, whilst in stage II - 1 relapse occurred, in stage III - 5 relapses, and in stage IV - 7 relapses.
  • The mean time of achieving complete remission was 67 days in patients demonstrating relapse and 59 days in non-relapsed patients.
  • In patients with relapse the mean initial serum lactate dehydrogenase (LDH) level was significantly lower than in non-relapsed group.
  • Among relapsed patients, 12 (92%) were EBV-seropositive at diagnosis, whereas only 13 (42%) in the group of non-relapsed patients.
  • In the subgroup of children with primary bone marrow involvement the mean absolute count of lymphoblasts in peripheral blood measured at diagnosis was 38.5 G/L in relapsed children and 5.2 G/L in non-relapsed children.
  • In the studied group EBV-seropositivity and initial lower serum LDH level are suggested to be risk factors of relapse of the lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / blood. Lymphoma, Non-Hodgkin / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531831.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


10. Di Lucca-Chrisment J, Maubec E, Grossin M, Marinho E, Varet B, Maillard H, Crickx B: [Long-term efficacy of autologous stem cell transplantation for stage IV mycosis fungoides]. Ann Dermatol Venereol; 2009 Nov;136(11):800-5
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term efficacy of autologous stem cell transplantation for stage IV mycosis fungoides].
  • [Transliterated title] Efficacité a long terme d'une autogreffe de cellules souches au cours d'un mycosis fongoïde de stade IV.
  • BACKGROUND: Mycosis fungoides during large cell transformation to lymphoma has a poor prognosis with mean survival of 36 months.
  • Autologous stem cell transplantation is rarely proposed in this indication.
  • We report the case of a young man still in complete remission for transformed mycosis fungoides 14 years after autologous stem cell transplantation.
  • CASE REPORT: A 25-year-old man presenting eczema-like patches since childhood was treated by chemotherapy for multiple lymphadenopathies considered as Hodgkin's lymphoma.
  • Histology of tumour samples revealed atypical T-cell infiltrate with epidermotropism and presence of more than 25% of large CD30-positive cells.
  • Non-infiltrated patches showed small T-cell lymphoma with epidermotropism.
  • Because of tumour aggressiveness, autologous stem cell transplantation was performed and resulted in rapid regression of the tumours, lymphadenopathy and neurological symptoms.
  • Non-transformed mycosis fungoides patches persisted but were controlled with topical mechlorethamine.
  • [MeSH-major] Mycosis Fungoides / pathology. Mycosis Fungoides / surgery. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917433.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


11. Uzurov-Dinić V, Savić A, Lazarević T, Cemerikić-Martinović V, Agić D, Popović S: [Prognostic factors in patients with diffuse large B-cell lymphoma]. Med Pregl; 2009 Mar-Apr;62(3-4):171-6
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors in patients with diffuse large B-cell lymphoma].
  • Diffuse large B-cell lymphoma is an aggressive type of lymphoma, potentially curable, with heterogeneous prognosis.
  • The retrospective study was done in 50 patients with diffuse large B-cell lymphoma.
  • The following parameters were investigated: demographic (age, sex), clinical (time to diagnosis, B symptoms, clinical stage), laboratory (erythrocyte sedimentarion rate, haemoglobin, lactate dehydrogenase, albumine), standard and revised international prognostic index, and immunohystochemical parameters, cluster designation 20, B-cell-2, and Ki67 expression.
  • The majority of patients had advanced disease: B symptoms in 76%, III and IV stage in 78%, increased lactate dehydrogenase in 74%, high risk standard international prognostic index in 62% of patients.
  • B-cell leukemia/lymphoma 2 expression was found in 57%, and high Ki67 in 62% of patients.
  • Our results have shown that international prognostic index, and complete remission status have prognostic significance in diffuse large B-cell lymphomas.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623849.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


12. Heinzelmann F, Ottinger H, Engelhard M, Soekler M, Bamberg M, Weinmann M: Advanced-stage III/IV follicular lymphoma: treatment strategies for individual patients. Strahlenther Onkol; 2010 May;186(5):247-54
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced-stage III/IV follicular lymphoma: treatment strategies for individual patients.
  • BACKGROUND: In patients with advanced-stage III/IV follicular lymphoma (FL), there are many treatment options available.
  • RESULTS: In advanced-stage III/IV FL, median survival may approach 8-10 years.
  • The use of autologous hematopoietic stem cell transplantation (HSCT) for patients in first remission or chemosensitive relapse prolongs progression-free survival while the effect on overall survival remains unclear compared to standard chemotherapy.
  • [MeSH-major] Lymphoma, Follicular / pathology. Lymphoma, Follicular / therapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2003 Jan;31(2):73-8 [12621486.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1263-70 [12663713.001]
  • [Cites] Semin Radiat Oncol. 1995 Oct;5(4):301-315 [10717153.001]
  • [Cites] Bone Marrow Transplant. 2005 Aug;36(3):205-13 [15937505.001]
  • [Cites] Haematologica. 2007 May;92(5):627-34 [17488686.001]
  • [Cites] Blood. 2004 Jan 15;103(2):725-31 [12947008.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4143-9 [16896003.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1014-22 [16878325.001]
  • [Cites] Eur J Haematol. 2002 Mar;68(3):144-9 [12068794.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):445-50 [9053464.001]
  • [Cites] Blood. 2005 May 15;105(10):3817-23 [15687232.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1691-8 [15520073.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4416-23 [14976046.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3918-27 [14517188.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1466-70 [12459371.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3595-9 [11739162.001]
  • [Cites] Blood. 2004 Dec 15;104(13):3865-71 [15304395.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10 ):2453-63 [12011122.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5156-64 [18854568.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3614-20 [18559872.001]
  • [Cites] Bone Marrow Transplant. 2002 Jun;29(12):973-8 [12098065.001]
  • [Cites] Strahlenther Onkol. 2007 Feb;183(2):99-106 [17294115.001]
  • [Cites] Bone Marrow Transplant. 1997 May;19(10):977-82 [9169641.001]
  • [Cites] Cancer. 2007 May 1;109 (9):1804-10 [17380530.001]
  • [Cites] Strahlenther Onkol. 2007 Jan;183(1):17-22 [17225941.001]
  • [Cites] Ann Hematol. 2003 Jul;82(7):458-62 [12756499.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4579-86 [18662969.001]
  • [Cites] Bone Marrow Transplant. 2005 Feb;35(3):233-41 [15592494.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:226-32 [18024634.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4003-8 [16946304.001]
  • [Cites] Leuk Lymphoma. 1999 Jun;34(1-2):129-36 [10350340.001]
  • [Cites] Bone Marrow Transplant. 2003 Jul;32(2):131-7 [12838276.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8447-52 [16230674.001]
  • [Cites] Strahlenther Onkol. 2006 Apr;182(4):222-30 [16622624.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):311-21 [15491292.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1177-84 [8201380.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1832-6 [9716615.001]
  • [Cites] Strahlenther Onkol. 2003 Oct;179(10):694-701 [14566478.001]
  • [Cites] Strahlenther Onkol. 2009 Nov;185(11):751-5 [19899009.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3521-9 [12893748.001]
  • [Cites] Br Med J. 1978 Mar 4;1(6112):533-7 [630211.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23 (10 ):2215-23 [15684317.001]
  • [Cites] Clin Lymphoma. 2004 Sep;5(2):98-101 [15453924.001]
  • [Cites] Blood. 2004 Jan 15;103(2):428-34 [12969983.001]
  • [Cites] Semin Hematol. 1988 Apr;25(2 Suppl 2):11-6 [2456618.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Lancet. 2003 Aug 16;362(9383):516-22 [12932382.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1986-92 [17420513.001]
  • [Cites] Strahlenther Onkol. 2009 Aug;185 Suppl 2:13-6 [19685028.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2474-80 [12829665.001]
  • [Cites] Br J Haematol. 1998 Jan;100(1):198-206 [9450812.001]
  • [Cites] Strahlenther Onkol. 2009 Aug;185 Suppl 2:17-20 [19685029.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1110-7 [9060552.001]
  • [Cites] Ann Oncol. 2000 Dec;11(12):1585-90 [11205467.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2667-74 [15238420.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1582-9 [16575009.001]
  • [Cites] Blood. 2008 Dec 15;112(13):4824-31 [18799723.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):441-9 [15689582.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):527-36 [10653868.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):140-7 [7799014.001]
  • [Cites] Australas Radiol. 2006 Jun;50(3):222-7 [16732818.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3325-33 [10552941.001]
  • [Cites] Strahlenther Onkol. 2007 Oct;183(10):545-51 [17896085.001]
  • [Cites] Radiother Oncol. 1997 Jan;42(1):49-51 [9132826.001]
  • [Cites] Ann Oncol. 2003 May;14(5):737-44 [12702528.001]
  • [Cites] Strahlenther Onkol. 2008 Sep;184(9):484-7 [19016028.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1S2):9-15 [28140221.001]
  • [Cites] Hematol Oncol. 1994 Jan-Feb;12(1):1-8 [8194839.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):148-55 [11516864.001]
  • [Cites] Strahlenther Onkol. 2005 Jun;181(6):385-91 [15925981.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4310-6 [12393626.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):782-7 [15183481.001]
  • [Cites] Blood. 1998 Jan 1;91(1):331-9 [9414302.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):644-51 [8478660.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1096-102 [7738615.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3295-301 [16873669.001]
  • [Cites] Blood. 1994 Aug 15;84(4):1050-5 [8049425.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:23-7 [10707774.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2540-4 [16835383.001]
  • [Cites] Blood. 1995 Oct 15;86(8):3257-62 [7579423.001]
  • [Cites] Blood. 2002 Jun 15;99(12 ):4336-42 [12036859.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23 (24):5696-704 [16110029.001]
  • [Cites] Bone Marrow Transplant. 2002 Aug;30(4):229-34 [12203139.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • (PMID = 20437015.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 92
  •  go-up   go-down


13. Groot MT, Lugtenburg PJ, Hornberger J, Huijgens PC, Uyl-de Groot CA: Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur J Haematol; 2005 Mar;74(3):194-202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands.
  • OBJECTIVE: To determine the incremental cost-effectiveness ratio (ICER) of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) vs. CHOP plus rituximab (R-CHOP) in diffuse large B-cell lymphoma (DLBCL) patients in the Netherlands.
  • METHODS: A state transition model was developed to estimate the clinical course, costs and quality of life of patients with stage II, III or IV DLBCL receiving initial treatment with CHOP or R-CHOP to arrive at the ICER.
  • [MeSH-major] Antibodies, Monoclonal / economics. Lymphoma, Large B-Cell, Diffuse / economics
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / economics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Budgets. Cost-Benefit Analysis. Decision Making. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / economics. Lymphoma, B-Cell / mortality. Monte Carlo Method. Netherlands. Quality of Life. Rituximab. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693788.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


14. Cunningham D, Smith P, Mouncey P, Qian W, Pocock C, Ardeshna KM, Radford J, Davies J, McMillan A, Linch D: A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma.
  • : 8506 Background: The addition of rituximab to standard therapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP21) has resulted in improved survival outcomes in the treatment of diffuse large B-cell non-Hodgkin's lymphoma (DLBC NHL).
  • Patient characteristics in the R-CHOP21 and R-CHOP14 arms are; IPI score of ≥4 17%:15%, stage III/IV disease 63%:62%, B symptoms 44%:47%, bulk disease 51%:48%.
  • Reported grade III/IV toxicities in the R-CHOP21 and R-CHOP14 arms are; neutropenia 57%:31%, thrombocytopenia 5%:9%, Infection 22%:17%, cardiac 1%:2%, nausea & vomiting 8%:8%, mucositis 2%:3%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960856.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Nabil IN Jr, Allam W, Alaoui K, Errihani H: Primary nasopharyngeal non Hodgkin lymphoma: A retrospective investigation of 26 patients. J Clin Oncol; 2009 May 20;27(15_suppl):e19552

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary nasopharyngeal non Hodgkin lymphoma: A retrospective investigation of 26 patients.
  • : e19552 Background: Primary nasopharyngeal non-Hodgkin lymphoma (NNHL) was uncommon.
  • METHODS: We retrospectively analyzed various characteristics of Primary NNHL: patient demographics, clinical and histological diagnosis, disease stage, treatment effects and outcome, in 26 patients treated at our institution between January 2001 and December 2007.
  • Histological analysis showed follicular lymphoma in 7 cases (26.9%), large B-cell lymphoma in 11 cases (42,3%) and T lymphoma in 4 cases ( 15,3%).
  • Four (15.4%) of the patients were at stage I, 15 (57.6%) were at stage II, and 7 (27%) were at stage III/IV.
  • At early stage, the patients were managed with chemo-radiotherapy and were managed with CHOP based chemotherapy at advanced stage.
  • CONCLUSIONS: From our study and from the literature, we conclude that histological characteristics, principle of treatment and outcome of primary NNHL patients are similar to that of patients with nodal lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961093.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Yoo C, Sohn B, Kim J, Yoon D, Huh J, Kim S, Lee D, Kim S, Lee J, Suh C: The prognostic significance of the number of extranodal sites in the patients with disseminated diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol; 2009 May 20;27(15_suppl):8570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic significance of the number of extranodal sites in the patients with disseminated diffuse large B-cell lymphoma treated with R-CHOP.
  • : 8570 Background: The combination of rituximab and CHOP chemotherapy (R-CHOP) has improved survival of patients with diffuse large B-cell lymphoma (DLBCL).
  • METHODS: Between January 2002 and May 2008, 126 patients with stage III/IV DLBCL treated with R-CHOP were identified.
  • Although all three indices remain predictive, E-IPI is the best model to identify the prognostic group in this cohort with stage III/IV DLBCL treated with R-CHOP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961016.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Martin MG, Cashen AF: SEER analysis of subcutaneous panniculitis-like T-cell lymphoma (SPTL). J Clin Oncol; 2009 May 20;27(15_suppl):e19527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SEER analysis of subcutaneous panniculitis-like T-cell lymphoma (SPTL).
  • Stage was available on 27 patients: 16 (59%) were Stage I/II and 11 were stage III/IV.
  • There was no difference in gender, ethnicity or stage distribution between those < 50 and ≥ 50.
  • 5-year lymphoma specific survival was 51%; 5-year OS was 41%.
  • Lymphoma specific survival was also significantly longer in the younger patients (G-B-W p=0.0015).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960920.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Xiao J, Guo C, Zhai L, Li H, Fu X, Huang Y, Huang Y, Huang J, Pu X, Lin T, Ye S: Prognostic value of different B symptoms in upper aerodigestive tract NK/T-cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19544

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of different B symptoms in upper aerodigestive tract NK/T-cell lymphoma.
  • : e19544 Background: Extranodal NK/T-cell lymphoma (ENKL) is a rare disease originated from NK or toxic T cells.
  • 98 cases were Ann Arbor stage I, 54 were stage II and the remaining 20 cases were stage III or IV.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960997.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Ridolfi L, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Valmorri L, Riccobon A, Ridolfi R: Dendritic cell vaccination in melanoma patients: Update and subgroup analysis of clinical response to post-vaccine treatment. J Clin Oncol; 2009 May 20;27(15_suppl):9042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell vaccination in melanoma patients: Update and subgroup analysis of clinical response to post-vaccine treatment.
  • In the literature, higher response rates than those normally obtained have been reported after second-line chemotherapy in patients with non small cell lung cancer pre-treated with vaccines and in patients with follicular B-cell lymphoma vaccinated with an anti-idiotype vaccine whilst in remission.
  • On the basis of this data, we reviewed and updated the clinical results of our dendritic cell based vaccine clinical trial in stage IV melanoma patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962107.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Giaccone G, Rajan A, Carter C, Kelly R, Berman A, Spittler J, Espinoza-Delgado I, Lee M, Trepel J, Loehrer P: Phase II study of the histone deacetylase inhibitor belinostat in thymic malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):7589

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Belinostat is an HDAC inhibitor with activity in cutaneous and peripheral T cell lymphoma and is being investigated in several solid tumors.
  • Belinostat was given iv at 1.0 g/m<sup>2</sup> on days 1-5 of a 21-day cycle until disease progression or intolerable side effects.
  • CONCLUSIONS: The thymoma cohort has been expanded to the second stage of the study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963413.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Joshi MM, Seligmann B, Sabalos C, Harpole DH Jr: Measurement of gene expression biomarkers by qNPA from archived NSCLC FFPE: Prognosis of 5-year survival. J Clin Oncol; 2009 May 20;27(15_suppl):11098

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, a method for measuring gene expression from FFPE using the quantitative Nuclease Protection Assay (qNPA) has been published in a model of diffuse large B-cell lymphoma.
  • METHODS: This study used the qNPA assay to measure gene expression in archived FFPE primary tumor samples of patients with stage 1 NSCLC for whom the survival outcomes are known (n=86).
  • CONCLUSIONS: These results suggest an improved survival advantage in patients with an elevated native GCSF level in stage 1 NSCLC that is consistent with the survival benefits associated with the prophylactic treatment of GCSF for chemosensitivity in stage III or IV NSCLC patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963124.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Delmer A, Fitoussi O, Gaulard P, Laurent G, Bordessoule D, Morschhauser F, Ferme C, Tilly H, Gisselbrecht C, Coiffier B, Groupe d'Etude des Lymphomes de l'Adulte (GELA): A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05-1T trial. J Clin Oncol; 2009 May 20;27(15_suppl):8554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05-1T trial.
  • : 8554 Background: Patients with peripheral T/NK cell lymphomas (PTCL) still have a dismal prognosis with 5-yr survival less than 30% in most cases.
  • RESULTS: 57 eligible pts (M 38, F 19, median age 52.5 yrs) with mostly AITL and PTCL NOS subtypes were enrolled between January 2006 and November 2007; 78% had stage III-IV disease and 53% had aaIPI ≥ 2.
  • As of November 14<sup>th</sup>, 2008, 22 pts (39%) have died, mostly from lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960989.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Flowers C, Sinha R, Kaufman J, Shenoy P, Lewis C, Bumpers K, Rogatko A: Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results. J Clin Oncol; 2009 May 20;27(15_suppl):8577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results.
  • : 8577 Background: Adding rituximab (R) to chemotherapy improves survival for patients (pts) with follicular lymphoma (FL) and other indolent non-Hodgkin lymphomas (NHL), but not all pts respond.
  • The maximum tolerated dose (MTD) was defined as the regimen at which <30% grade ≥3 non-hematological or grade ≥4 hematological toxicity (>14 days) occurs.
  • 6 pts (55%) had stage IV disease; 8 (64%) had FLIPI ≥2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962274.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Milani C, Castillo J: HIV-associated peripheral T-cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated peripheral T-cell lymphoma.
  • : e19551 Background: T-cell lymphomas (TCL) constitute 3% of all AIDS-related lymphomas.
  • These lymphomas comprise a diverse group of disease entities, including peripheral T-cell lymphomas (PTCL), which represent the most common subtype.
  • Data regarding patient age, gender, HIV status (CD4 count, viral load, opportunistic infections), use of HAART, lymphoma features (B symptoms, stage, sites of involvement, immunophenotype, molecular studies), EBV coinfection, therapy, and outcome (survival, cause of death) were analyzed and reported descriptively.
  • Stage III and IV disease was found in 17 and 5 cases, respectively, accounting for 76% of the total cases.
  • T-cell receptor gene rearrangement was positive in 10 out of 10 (100%) analyzed cases.
  • Twenty-two patients (69%) died complicated by infections in 57% and lymphoma progression in 36% of cases.
  • Apart from marked immunosuppression, the poor prognosis of HIV-associated PTCL appears to be related to advanced stage at presentation, presence of B symptoms, elevated LDH levels, prominent extranodal disease, and poor response to CHOP chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961094.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Vera L, Reategui R, Beltran B, Morales D, Capellino A, Desposorio C, Castillo J: The clinicopathological spectrum of HIV-associated lymphoma: Eleven-year-experience in a general hospital in Peru. J Clin Oncol; 2009 May 20;27(15_suppl):e19561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinicopathological spectrum of HIV-associated lymphoma: Eleven-year-experience in a general hospital in Peru.
  • RESULTS: Forty-eight patients with HIV-associated lymphoma were identified.
  • 32 patients (67%) had clinical stage III-IV, B symptoms 35 (73%), the International Prognostic Index was low-risk 20 patients (42%), low-intermediate risk 15 patients (31%), high-intermediate risk 10 patients (21%) and high-risk 3 patients (6%).
  • Forty-four cases (92%) were diagnosed with non-Hodgkin lymphoma (NHL) and 4 cases (8%) with Hodgkin lymphoma (HL).
  • From the 44 NHL cases, 40 cases (91%) were of B-cell origin; 23 cases (57.5%) had diffuse large B-cell, 9 cases (22.5%) had Burkitt, 3 cases (7.5%) had plasmablastic, 2 cases (5%) had primary CNS, 2 cases (5%) had MALT and 1 case (2.5%) had primary effusion lymphoma.
  • The remaining 4 cases (9%) were of T-cell origin; 3 cases (75%) had peripheral T-cell lymphoma NOS and 1 case (25%) was ALK-negative anaplastic large cell lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961062.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Geskin L, Sun Y, Gao J: Impact of the number of cycles on efficacy of denileukin diftitox (Dd) in subjects with cutaneous T-cell lymphoma (CTCL). J Clin Oncol; 2009 May 20;27(15_suppl):e19549

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of the number of cycles on efficacy of denileukin diftitox (Dd) in subjects with cutaneous T-cell lymphoma (CTCL).
  • METHODS: Subjects received Dd doses of 9 or 18 mcg/kg IV daily for 5 days, repeating every 21 days for up to 8 courses.
  • The majority of subjects had CTCL stage ≤ IIa at baseline.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960976.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Gerrard M, Waxman I, Sposto R, Auperin A, Harrison L, Pinkerton R, Perkins SL, McCarthy K, Raphael M, Patte C, Cairo MS, FAB/LMB 96 Trial: Association of primary mediastinal B-cell lymphoma (PMBL) in children (C) and adolescents (A) with a significantly inferior prognosis: Final results of the FAB/LMB 96 trial. J Clin Oncol; 2009 May 20;27(15_suppl):10001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of primary mediastinal B-cell lymphoma (PMBL) in children (C) and adolescents (A) with a significantly inferior prognosis: Final results of the FAB/LMB 96 trial.
  • : 10001 Background: Single pediatric cooperative group studies have demonstrated an EFS ranging from 65 - 75% in C & A with large cell lymphomas arising in the mediastinum (Lones/Cairo et al, J Clin Oncol, 2000; Burkhardt/Reiter et al, Br J Haematol, 2005; Seidman/Reiter et al, J Clin Oncol, 2003).
  • Recently, Staudt and Shipp have independently demonstrated that following gene expression profiling by oligonucleotide microarray that PMBL resembles more like classical Hodgkin lymphoma than diffuse large B-cell lymphoma with enhanced NF-κB pathway gene expression (Rosenwald et al, J Exp Med, 2003; Abramson et al, Blood, 2005).
  • RESULTS: There were 528 patients with stage III/IV disease treated on group B therapy on FAB/LMB 96 resulting in a 2 yr EFS of 84% (CI<sub>95</sub>: 82-86%).
  • 5 yr EFS was significantly inferior compared to the remainder of the other patients with stage III disease treated on group B therapy (54%: CI<sub>95</sub> 38-68% vs 85%: CI<sub>95</sub> 81-88%) (p < 0.001).
  • CONCLUSIONS: PMBL in C & A is associated with a significantly inferior EFS compared to other histological forms of stage III/IV mature B-NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962546.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Rodriguez MA, Wei W, Huang X, Fisch M, Durand JB: Evaluation of brain natriuretic peptide (BNP), troponin levels, and left ventricular ejection fraction (LVEF) in older adults with diffuse large B cell lymphoma (DLBCL). J Clin Oncol; 2009 May 20;27(15_suppl):e19506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of brain natriuretic peptide (BNP), troponin levels, and left ventricular ejection fraction (LVEF) in older adults with diffuse large B cell lymphoma (DLBCL).
  • METHODS: DRCOP is: Rituximab 375 mg/m2 IV day (d) 1; D 40 mg/m2 IV d 1; cyclophosphamide 750 mg/m2 IV d 1; vincristine 2 mg IV d 1 total dose; prednisone 100 mg/d p.o. d 1-5.
  • Eligibility criteria: > 60 years; untreated DLBCL; Ann Arbor stage II-IV; baseline LVEF ≥ 50%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960865.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Morales D, Beltran B, Hurtado de Mendoza F, Riva L, Quiñones P: Analysis of prognostic factors in patients with EBV positive diffuse large B cell lymphoma of the elderly. J Clin Oncol; 2009 May 20;27(15_suppl):e19542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors in patients with EBV positive diffuse large B cell lymphoma of the elderly.
  • : e19542 Background: EBV positive diffuse large B cell lymphoma of the elderly is a new entity included in the Fourth edition of WHO Classification.
  • AIM: The goal of this study was to evaluate clinical characteristics and survival of EBV positive diffuse large B cell lymphoma of the elderly from Peruvian patients.
  • METHODS: Between January 2002 and June 2008, eleven patients with EBV positive diffuse large B cell lymphoma of the elderly were included in the analysis.
  • Stage: I (n=1), II (n=1), III (n=5) and IV (n=4).
  • Ten cases (83%) were of the Non-GC and 1 case was GC.
  • CONCLUSIONS: EBV positive diffuse large B cell lymphoma of the elderly was related to high IPI, poor ECOG, frequent extranodal disease, poor response to treatment and very short survival.
  • It is the first report of this entity in a non-Asian population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960995.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Dang NH, Sun Y, Gao J: Effect of dose on denileukin diftitox (Dd) response in treatment-naïve cutaneous T-cell lymphoma (CTCL) subjects: A retrospective analysis of three phase III studies. J Clin Oncol; 2009 May 20;27(15_suppl):e19509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of dose on denileukin diftitox (Dd) response in treatment-naïve cutaneous T-cell lymphoma (CTCL) subjects: A retrospective analysis of three phase III studies.
  • METHODS: Studies 10 and 11 included early or advanced stage CD25(+) subjects (CD25 immunostaining in >20% of malignant cells) while 14 included CD25(-).
  • Subjects received 9 or 18 mcg/kg/day IV for 5 days, repeating every 21 days for up to 8 courses; subjects in study 14 only received the higher dose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960866.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Yamaguchi M, Tobinai K, Oguchi M, Isobe Y, Ishizawa K, Maseki N, Wasada I, Ishizuka N, Hotta T, Oshimi K, Japan Clinical Oncology Group, Lymphoma Study Group (JCOG-LSG): Phase I/II study of concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma: Final results of JCOG0211. J Clin Oncol; 2009 May 20;27(15_suppl):8549

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma: Final results of JCOG0211.
  • : 8549 Background: Nasal NK/T-cell lymphoma is rare and its standard therapy has not been established.
  • METHODS: To explore a more effective treatment for localized nasal NK/T-cell lymphoma, we conducted a phase I/II study of concurrent chemoradiotherapy consisted of 50 Gy of RT and 3 courses of DeVIC [carboplatin (CBDCA), etoposide (ETP), ifosfamide (IFM), dexamethasone (DMS)].
  • Based on the results of the phase I portion (ASH 2005, #2685), 2/3-dose of DeVIC (CBDCA 200mg/m<sup>2</sup> d1 IV, ETP 67mg/m<sup>2</sup> d1-3 IV, IFM 1.0g/m<sup>2</sup> d1-3 IV, DMS 40mg/body d1-3 IV; every 3 wks) was applied for the phase II portion.
  • 27 pts evaluated in the phase II portion showed the following features: age 21-68 yrs (median 56), M:F=17:10, stage IE 18, stage IIE 9, B symptom (+) 10, elevated serum LDH 5, PS2 2.
  • The most common grade 3 non-hematologic toxicities were mucositis due to RT (30%) and infection (30%).
  • CONCLUSIONS: Concurrent chemoradiotherapy using MDR-non-related agents and ETP is a safe and effective treatment for localized nasal NK/T-cell lymphoma, providing the basis for subsequent studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960966.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Duvic M, Forero-Torres A, Foss F, Olsen E, Pinter-Brown L, Kim Y: Long-term treatment of CTCL with the oral PNP inhibitor, forodesine. J Clin Oncol; 2009 May 20;27(15_suppl):8552

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8552 Background: Forodesine is a potent inhibitor of purine nucleoside phosphorylase (PNP) that leads to T-cell selective intracellular accumulation of dGTP, resulting in apoptosis.
  • Subjects with refractory CTCL, stages IB-IV were eligible.
  • Six discontinued treatment (median time on treatment 440 days): 4 for progressive disease, 1 withdrew consent, and 1 due to an adverse event (Diffuse Large B-cell Lymphoma).
  • Median age was 68 years (range 42, 81), and all but one was ≥ stage III.
  • Grade 3 or higher related AEs were experienced by 2 of 9 subjects (Diffuse Large B-Cell Lymphoma as previously mentioned and peripheral edema).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960987.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Muslimani A, Spiro T, Chaudhry A, Taylor H, Jaiyesimi I, Elson P, Daw H: Value of International Prognostic Score (IPS) in predicting need for bone marrow biopsy (BMB) in Hodgkin's lymphoma (HL). J Clin Oncol; 2009 May 20;27(15_suppl):e19531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of International Prognostic Score (IPS) in predicting need for bone marrow biopsy (BMB) in Hodgkin's lymphoma (HL).
  • The IPS is calculated as the number of poor risk features present based on male sex, age ≥45, albumin (alb) <4 g/dL, hemoglobin (hem) <10.5 g/dL, stage IV, white blood cell (WBC) ≥15,000/mm<sup>3</sup>, lymphocyte (lymph) <600/mm<sup>3</sup> and/or <8% of total WBC.
  • All 7 factors were significant (p<.001 for sex, age, albu, hem, stage and lymph; .07 for WBC); and therefore recursive partioning algorithm was used to identify a cutoff for determining bone marrow involvement (BMI).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961027.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Castillo J, Milani C, Pantanowitz L: HIV-associated anaplastic large cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19563

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated anaplastic large cell lymphoma.
  • : e19563 Background: Anaplastic large cell lymphoma (ALCL) is a CD30+ T-cell lymphoma that is generally unrelated to EBV in the non-HIV setting.
  • Based upon anaplastic lymphoma kinase (ALK) expression, the new WHO classification provisionally distinguishes between ALK+ (favorable) and ALK- (unfavorable) ALCL.
  • METHODS: A MEDLINE search for all cases of HIV-associated non-cutaneous ALCL was undertaken.
  • Data regarding patient age, gender, HIV status (CD4 count, viral load, opportunistic infections), HAART, lymphoma features (B symptoms, stage, sites of involvement, immunophenotype, ALK expression, molecular studies), EBV coinfection, therapy and outcome (survival, cause of death) were extracted and analyzed.
  • Many (78%) patients had stage IV disease and B symptoms were reported in 9 cases (50%).
  • T-cell receptor gene rearrangement was present in all cases, CD30 was positive in 22 (96%), and the vast majority (90%) were ALK-negative.
  • Death was caused by either lymphoma progression (42%) or infection (58%).
  • CONCLUSIONS: HIV-associated non-cutaneous ALCL appears to affect younger individuals and is associated with EBV infection in a subset of cases.
  • Apart from marked immunosuppression, the poor prognosis of HIV-associated ALCL appears to be related to the absence of ALK expression, advanced stage at presentation with prominent extranodal disease, inadequate therapy including HAART, and poor response to CHOP.
  • Further research is needed to better understand and treat this unique HIV-associated lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961064.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Miyazaki K, Yamaguchi M, Suzuki R, Niitsu N, Ennishi D, Tamaru J, Kagami Y, Katayama N, Kinoshita T, Nakamura S: Retrospective analysis of CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) treated with chemotherapy with or without rituximab. J Clin Oncol; 2009 May 20;27(15_suppl):8551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) treated with chemotherapy with or without rituximab.
  • Intravascular large B-cell lymphoma, primary CNS DLBCL, and secondary CD5+ DLBCL were excluded from the study population.
  • RESULTS: 313 pts showed the following clinical features: median age, 67 (range: 15-93); M:F=163:150; elevated serum LDH level, 71%; stage III/IV, 64%; IPI HI/H, 53%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960955.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Bose P, Thompson CL, Gandhi DG, Ghabach BS, Ozer H: Response of AIDS-related plasmablastic lymphoma (PBL) to bortezomib. J Clin Oncol; 2009 May 20;27(15_suppl):e19562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of AIDS-related plasmablastic lymphoma (PBL) to bortezomib.
  • They are terminally differentiated B-cell neoplasms, and typically lack common B-cell markers but uniformly express plasma cell markers.
  • Flow cytometry was negative for CD45 and all common epithelial, T-cell and B-cell markers, but was positive for CD138 and p63(VS38c).
  • The diagnosis was stage IVBE PBL.
  • Bortezomib was then administered at a dose of 1.3 mg/m2 IV on days 1, 4, 8 and 11.
  • The WHO classifies PBL as a variant of diffuse large B-cell lymphoma.
  • However, studies of their immunophenotype and molecular histogenesis suggest that PBL are more closely related to plasma cell neoplasms.
  • Bortezomib is a proteasome inhibitor widely used in multiple myeloma and mantle cell lymphoma.
  • We chose bortezomib based on our patient's poor performance status and immune function, the desire to avoid combination chemotherapy, and translocations involving the immunoglobulin heavy chain gene locus (8;14) similar to those seen in multiple myeloma(4;14, 14;16) and mantle cell lymphoma(11;14).
  • A shift in the paradigm of treatment of PBL towards agents effective in plasma cell malignancies may be necessary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961065.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Johnston PB, LaPlant B, Kurtin P, Habermann T, Moore D, Nabbout N, Nikcevich D, Rowland K, Witzig T: Salvage chemotherapy with rituximab, oxaliplatin, cytosine arabinoside, and dexamethasone (ROAD) in patients with relapsed CD20+ aggressive B-cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8556

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with rituximab, oxaliplatin, cytosine arabinoside, and dexamethasone (ROAD) in patients with relapsed CD20+ aggressive B-cell lymphoma.
  • Patients were considered for autologous stem cell transplantation after 2 cycles if eligible.
  • Eligible histologies included diffuse large B cell lymphoma, mantle cell lymphoma and transformed lymphoma in first relapse.
  • Baseline characteristics of eligible patients included median age 69 (range 23 - 77), 53% were male, 53% had advanced stage at relapse, LDH was elevated in 58% and all patients had an ECOG PS of 2 or less.
  • 31 patients experienced grade III/IV hematologic toxicity and 22 patients had grade III/IV non-hematologic toxicity, primarily febrile neutropenia.
  • CONCLUSIONS: ROAD is a safe and effective salvage chemotherapy regimen for relapsed aggressive lymphoma, including as a preparatory regimen prior to stem cell transplant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960991.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Reiter A, Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Mann G, Schrappe M: Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol; 2009 May 20;27(15_suppl):10000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin lymphoma (NHL).
  • : 10000 Background: Pediatric mature B-cell NHL differ from aggressive B-NHL of adults in terms of biology and treatment outcome.
  • TREATMENT: Rx 375 mg/m<sup>2</sup> IV at day 1; concomitant therapy: Rasburicase, steroids only for anaphylaxis, intrathecal (IT) triple drug at days 1, 3 for CNS+ pts only.
  • Study plan: Simon 2-stage phase II with α and β = 5%.
  • 33 pts entered the first stage, final evaluation after 79 pts.
  • RR by histology: BL/B-ALL 29/68, DLBCL 6/14, juvenile follicular lymphoma 1/2, PMBCL 1/1, B-NHL nfs 0/2.
  • Fifty pts were non-RPs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962545.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Weyl Ben Arush M Sr, Hersalis Eldar A, Abrahami G, Attias D, Ben Barak A, Dvir R, Gabriel H, Kapelushnik J, Kaplinsky H, Vilk-Revel S: Burkitt lymphoma in children: The Israel Society of Pediatric Hematology Oncology retrospective study. J Clin Oncol; 2009 May 20;27(15_suppl):10051

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in children: The Israel Society of Pediatric Hematology Oncology retrospective study.
  • : 10051 Background: From 2000 to 2005, the Israel Society of Pediatric Hematology Oncology studied the results of the FAB-LMB 96 protocol in children with B cell lymphoma.
  • Fifty patients (57%) were classified as burkitt lymphoma, 5 (5.7%) as burkitt-like lymphoma, 22 (25%) as diffuse large B cell (DLBC), 9 (10.2%) as burkitt leukemia.
  • Stage I: 9.1%, Stage II in 28.4%, stage III in 45.5%, stage IV in 17%.
  • CONCLUSIONS: In nonresected mature B cell lymphoma of childhood and adolescence with no BM or CNS involvement, a 93% cure rate was achieved.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962447.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Pajares-Hachero B, Torres E, Hierro I, Jurado JM, Rueda A: Mantle cell lymphoma stage IV affecting lacrimal glands, retro-orbital tissue, optic nerve and ocular motor muscles. Clin Transl Oncol; 2009 Jul;11(7):484-5
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma stage IV affecting lacrimal glands, retro-orbital tissue, optic nerve and ocular motor muscles.
  • Mantle cell lymphoma (MCL) is an entity which exceptionally affects the ocular region and periorbital tissues, but which should be included in the differential diagnosis of lesions which affect the orbital region in a diffused manner.
  • We report the case of a 60-year-old patient diagnosed with stage IV MCL, whose fi rst clinical manifestation was a result of the damage of lacrimal glands, retro-orbital tissue and ocular motor muscles.
  • [MeSH-major] Lacrimal Apparatus / pathology. Lymphoma, Mantle-Cell / pathology. Optic Nerve / pathology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Genetic Alliance. consumer health - Orbital lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biochem Cell Biol. 2007;39(10):1747-53 [17574898.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):750-62 [17891190.001]
  • [Cites] Ophthalmology. 2005 Jan;112(1):114-9 [15629830.001]
  • [Cites] Ann Oncol. 2006 Sep;17 (9):1418-23 [16766582.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7013-23 [16145068.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]
  • [Cites] Hematol Oncol. 2004 Dec;22(4):143-58 [16134191.001]
  • (PMID = 19574208.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


41. Todorovic M, Pavlovic M, Balint B, Kraguljac N, Mihaljevic B, Bogdanovic A, Elezovic I, Boskovic D, Colovic M: Immunophenotypic profile and clinical characteristics in patients with advanced stage mantle cell lymphoma. Med Oncol; 2007;24(4):413-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic profile and clinical characteristics in patients with advanced stage mantle cell lymphoma.
  • The objective of this study was to evaluate immunophenotypic profile along with clinical follow-up in patients with advanced stage mantle cell lymphoma (MCL), and their possible influence on overall survival (OS).
  • Bone marrow (BM) cell and/or peripheral blood mononuclear cell flow cytometric analyses of the following antigens were performed: HLA-DR, CD19, CD20, CD22, CD23, CD25, CD10, SmIg, kappa, lambda, CD79b, CD38, FMC7, CD3, CD2, and CD5.
  • There were 14 patients in IV CS, and 26 patients in CS V.
  • Median OS was 20 months, and there were no significant OS-differences between CS IV and leukemic phase patients.
  • [MeSH-major] Antigens, Surface / analysis. Biomarkers, Tumor / analysis. Immunophenotyping. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / therapy

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2006 Mar;48(4):353-62 [16487357.001]
  • [Cites] Eur J Immunol. 1997 Feb;27(2):572-5 [9045933.001]
  • [Cites] Am J Surg Pathol. 2006 Oct;30(10):1274-80 [17001159.001]
  • [Cites] Leuk Lymphoma. 2004 Oct;45(10):2007-15 [15370245.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1014-22 [16878325.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):1-7 [17057651.001]
  • [Cites] Blood. 1991 Jul 15;78(2):259-63 [2070063.001]
  • [Cites] Pathol Int. 2006 Aug;56(8):440-8 [16872438.001]
  • [Cites] Mod Pathol. 2006 Nov;19(11):1498-505 [16980950.001]
  • [Cites] Eur J Immunol. 1990 Jun;20(6):1259-64 [2142456.001]
  • [Cites] Acta Haematol. 2001;106(3):130-2 [11713380.001]
  • [Cites] Immunol Res. 1992;11(3-4):260-72 [1287120.001]
  • [Cites] Leukemia. 1998 Aug;12(8):1281-7 [9697885.001]
  • [Cites] Ann Hematol. 2007 Feb;86(2):101-5 [17089127.001]
  • [Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]
  • [Cites] Leuk Lymphoma. 1996 Mar;21(1-2):115-25 [8907278.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):567-75 [9452276.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Sep;169(2):169-73 [16938577.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):269-73 [12688344.001]
  • [Cites] Br J Haematol. 1998 May;101(2):302-10 [9609526.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4483-94 [8639814.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Nov;171(1):44-51 [17074590.001]
  • (PMID = 17917091.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Biomarkers, Tumor
  •  go-up   go-down


42. Mac Manus MP, Ryan G, Lau E, Wirth A, Hicks RJ: Positron emission tomography of stage IV mucosa-associated lymphoid tissue lymphoma confined to the four major salivary glands. Australas Radiol; 2007 Feb;51(1):68-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography of stage IV mucosa-associated lymphoid tissue lymphoma confined to the four major salivary glands.
  • In a patient with stage IVA marginal zone lymphoma, (18)F-fluorodeoxyglucose-positron emission tomography indicated that the disease was confined to the four major salivary glands.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / radionuclide imaging. Positron-Emission Tomography. Salivary Gland Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17217492.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


43. Lee HW, Kim K, Kim W, Ko YH: ALK-positive diffuse large B-cell lymphoma: report of three cases. Hematol Oncol; 2008 Jun;26(2):108-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma: report of three cases.
  • Diffuse large B-cell lymphoma positive for anaplastic lymphoma kinase (ALK(+) DLBCL) is a rare variant of diffuse large B-cell lymphoma, with characteristic morphological, immunohistochemical and cytogenetic features.
  • Only 34 cases of ALK-positive diffuse large B-cell lymphoma have so far been reported in the literature.
  • All of them had stage IV disease at initial presentation, with poor outcomes.
  • These three cases suggest that different types of cytogenetic aberrations may involve the ALK gene in ALK-positive diffuse large B-cell lymphoma leading to peculiar immunohistochemical staining patterns.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Protein-Tyrosine Kinases / biosynthesis. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Adult. Cell Nucleus / metabolism. Chromosome Aberrations. Cytogenetics. Female. Gene Deletion. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Receptor Protein-Tyrosine Kinases. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18220322.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


44. Oh SY, Kim WS, Lee DH, Kim SJ, Kim SH, Ryoo BY, Kang HJ, Choi YJ, Chung JS, Kim HJ, Suh C: Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. Invest New Drugs; 2010 Apr;28(2):171-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial.
  • BACKGROUND: Therapeutic approaches to marginal zone B-cell lymphoma (MZL) continue to evolve.
  • We conducted this multi-center, phase II trial to assess the efficacy and safety of gemcitabine single chemotherapy for patients with stage III/IV MZL.
  • Non-hematologic toxicities were mild and tolerable.
  • As the response rate in stage I did not justify progressing to stage II (> or = 8/15), this study had to be discontinued, in accordance with the established protocols.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cooperative Behavior. Deoxycytidine / analogs & derivatives. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 11):47-53 [7481845.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Cancer. 2008 Dec 1;113(11):3192-8 [18932253.001]
  • [Cites] Eur J Haematol. 2008 Feb;80(2):127-32 [18005385.001]
  • [Cites] Cancer. 2004 May 15;100(10):2190-4 [15139063.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4349-57 [9766663.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3349-52 [15867234.001]
  • [Cites] Am J Hematol. 2007 Jun;82(6):446-52 [17266060.001]
  • [Cites] J Natl Cancer Inst. 2004 Apr 21;96(8):586-94 [15100336.001]
  • [Cites] Ann Oncol. 2006 May;17 Suppl 4:iv18-24 [16702180.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2489-95 [12456507.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4157-64 [14615444.001]
  • [Cites] Cancer Treat Rev. 2009 Jun;35(4):335-9 [19131170.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):772-8 [11380469.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1835-42 [15386331.001]
  • [Cites] Breast Cancer Res Treat. 2008 Apr;108(3):319-31 [17530427.001]
  • [Cites] Adv Exp Med Biol. 2000;486:287-90 [11783501.001]
  • [Cites] Eur J Cancer. 2000 Oct;36(15):1974-83 [11000580.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):883-9 [18452104.001]
  • [Cites] Cancer Res. 1994 Aug 1;54(15):4138-43 [8033147.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8442-6 [16293875.001]
  • [Cites] Haematologica. 2000 Sep;85(9):926-9 [10980630.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18 Suppl):23S-33S [12235221.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2615-9 [10893294.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2524-9 [7595703.001]
  • [Cites] Exp Hematol. 1998 Dec;26(13):1223-8 [9845378.001]
  • [Cites] Hematology. 2007 Apr;12(2):149-53 [17454196.001]
  • [Cites] Am J Clin Oncol. 2005 Apr;28(2):165-8 [15803011.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3786-92 [10577850.001]
  • [Cites] Br J Haematol. 1999 Jul;106(1):78-85 [10444166.001]
  • [Cites] Int J Hematol. 2004 May;79(4):311-21 [15218957.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1254 [10561186.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1382-91 [14630277.001]
  • [Cites] Best Pract Res Clin Haematol. 2005 Mar;18(1):57-68 [15694184.001]
  • [Cites] Am J Clin Oncol. 2005 Apr;28(2):169-72 [15803012.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3872-7 [12228207.001]
  • [Cites] Blood. 2000 Feb 1;95(3):802-6 [10648389.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Oct;64(5):907-16 [19219604.001]
  • (PMID = 19421710.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


45. Saito A, Miyazawa Y, Isoda A, Hatsumi N, Matsumoto M, Kojima M, Sawamura M: [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)]. Rinsho Ketsueki; 2008 Feb;49(2):82-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)].
  • We retrospectively analyzed the clinical course and prognosis of 11 patients with angioimmunoblastic T-cell Lymphoma (AILT).
  • All patients were in clinical stage III or IV.
  • As the initial therapy, 10 patients received combination chemotherapy and only 1 patient received autologous peripheral blood stem cell transplantation.
  • [MeSH-major] Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341037.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


46. Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W, Mann G, Henze G, Niggli F, Ludwig WD, Janssen D, Riehm H, Schrappe M, Reiter A: Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol; 2006 Jan 20;24(3):491-9
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma.
  • PURPOSE: In the Non-Hodgkin's Lymphoma-Berlin-Frankfurt-Munster (NHL-BFM) 95 trial, we tested, against the historical control of the combined trials NHL-BFM90 and NHL-BFM86, whether prophylactic cranial radiotherapy (PCRT) can be omitted for CNS-negative patients with stage III or IV lymphoblastic lymphoma (LBL) with sufficient early response.
  • The target patient group consisted of stage III and IV patients who were CNS negative and responded well to induction therapy.
  • CONCLUSION: For CNS-negative patients with stage III or IV LBL and sufficient response to induction therapy, treatment without PCRT may be noninferior to treatment including PCRT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / prevention & control. Cranial Irradiation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16421426.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


47. Liu YH, Li L, Liu G, Zhuang HG, Luo DL, Luo XL, Xu J: [Gene expression profiling of diffuse large B-cell lymphoma in China]. Zhonghua Bing Li Xue Za Zhi; 2007 Feb;36(2):79-83
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gene expression profiling of diffuse large B-cell lymphoma in China].
  • OBJECTIVE: Gene expression profiling of diffuse large B-cell lymphoma (DLBCL) of different immunophenotypes.
  • Clinical stages of all 9 lymphomas were Ann Arbor stage IV.
  • Although Group B lymphomas showed mixed immunophenotypical features of both germinal center B-cell-like DLBCL (Group A) and activated B-cell-like lymphomas (Group C), gene profile clustering showed that Group B was dissimilar to Group A or Group C, with 45 over-expressed and 27 uniquely expressed genes.
  • The gene expression profile of Group B lymphomas suggests that factors other than the cell-of-origin may contribute to the pathogenesis of DLBCL.
  • [MeSH-major] Gene Expression Profiling. Immunophenotyping / methods. Lymphoma, Large B-Cell, Diffuse / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493379.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interferon Regulatory Factors; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


48. Yang BY, Yong WB, Zhu J, Zheng W, Zhang YT, Wang XP, Meng SN: [Clinical characteristics and prognosis of diffuse large B-cell lymphoma]. Zhonghua Zhong Liu Za Zhi; 2005 Mar;27(3):174-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
  • OBJECTIVE: To investigate the clinical characteristics of diffuse large B-cell lymphoma (DLBCL) and the factors affecting its prognosis.
  • Sex, age, clinical stage, performance status (PS), serum lactate dehydrogenase (LDH), number of extranodal lesions, treatment response, cycles of chemotherapy, B symptom, erythrocyte sedimentation rate (ESR), 5-year survival rate and median survival time (mST) were included as the analysis indeces.
  • Age, stage, PS, serum LDH, number of extranodal lesions, international prognostic index (IPI) and remission rates were significantly correlated with overall survival (OS) and mST (P < 0.05), However, sex, chemotherapy cycles, B symptom, ESR were not related to OS and mST (P > 0.05).
  • Age, stage, remission rates were identified as independent factors affecting the prognosis.
  • Combination of surgery and chemotherapy was quite impressive in the prolongation of survival of patients with extranodal lesions and gastrointestinal lymphoma compared to those by chemotherapy alone.
  • CONCLUSION: Age, stage, PS, serum LDH, number of extranodal lesions, IPI, chemotherapy cycles and remission rates are significant factors affecting the prognosis in DLBCL patients.
  • Age less than 40 years or >/= 65 years, Stage III-IV, partial remission or progressive disease are demonstrated as poor prognostic factors.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946571.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


49. Xia HL, Chen LJ, Chen B, Jin XL, Chen SJ: The molecular cytogenetic aberration analyzed by comparative genomic hybridization and its significance in diffuse large B-cell lymphoma. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Feb;23(1):12-5
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The molecular cytogenetic aberration analyzed by comparative genomic hybridization and its significance in diffuse large B-cell lymphoma.
  • OBJECTIVE: To identify genetic alterations in diffuse large B-cell lymphoma (DLBCL) and to analyse the relationship between the genetic aberrations and the clinical characteristics.
  • METHODS: Using comparative genomic hybridization (CGH) to investigate the genomic changes in 24 cases of DLBCL and to analyse the relationship between these aberrations and clinical parameters including Ann arbor stage, systemic symptoms, chemotherapy efficacy and survival.
  • RESULTS: Aberrations were detected in 62.5% patients of 24 cases; the most common chromosomal alterations included loss of 6q15-21 as well as gain of 18q11-ter, of which the incidences were 20.8% and 16.7%, respectively; with comparing clinical parameters between patients with normal CGH and abnormal CGH, we found that patients with abnormal CGH suffered more from stage III-IV and had higher incidence of systemic symptoms, poor chemotherapy efficacy and poor survival (P<0.05), but there was no difference observed in the incidence of extranodal involvement between two groups.
  • [MeSH-major] Chromosome Aberrations. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16456777.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


50. Halfdanarson TR, Rubio-Tapia A, Ristow KM, Habermann TM, Murray JA, Inwards DJ: Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphoma. Clin Gastroenterol Hepatol; 2010 Dec;8(12):1042-7
MedlinePlus Health Information. consumer health - Celiac Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphoma.
  • BACKGROUND & AIMS: Celiac disease (CD) is associated with an increased risk of lymphoma.
  • However, relatively few studies have assessed the outcome of patients diagnosed with both CD and lymphoma.
  • We evaluated the temporal association between lymphoma and CD, along with clinical presentation, response to therapy, and prognosis.
  • METHODS: Patients diagnosed with both CD and lymphoma were identified retrospectively in a tertiary referral center.
  • RESULTS: Sixty-three patients (36 men) were identified who had been diagnosed with lymphoma and CD.
  • Thirty-six (57%) were diagnosed with CD before they were diagnosed with lymphoma.
  • The most common histologic entity was diffuse, large, B-cell lymphoma, which affected 18 (29%) patients.
  • Complete information for staging was available in 59 patients; 24 (38%) had stage IV disease.
  • Survival of patients with T-cell lymphoma was shorter than for all other lymphomas (119.4 vs 22.8 mo; P = .02).
  • CONCLUSIONS: CD is associated with B- and T-cell lymphomas.
  • Patients with B-cell lymphomas had a better prognosis than those with T-cell lymphoma.
  • Therapy is unsatisfactory for enteropathy-type T-cell lymphoma.

  • Genetic Alliance. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] Lancet. 2000 Jul 15;356(9225):203-8 [10963198.001]
  • [Cites] Am J Gastroenterol. 2010 Jun;105(6):1412-20 [20145607.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1635-45 [12414511.001]
  • [Cites] Arch Intern Med. 2003 Feb 10;163(3):286-92 [12578508.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2517-24 [12815137.001]
  • [Cites] Gastroenterology. 2003 Jul;125(1):40-6 [12851869.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):730-45 [12949719.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Jan;1(1):19-27 [15017513.001]
  • [Cites] Lancet. 1978 Jan 14;1(8055):67-70 [74567.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):795-803 [10673521.001]
  • [Cites] Digestion. 2000;62(1):60-5 [10899727.001]
  • [Cites] Br Med J (Clin Res Ed). 1983 Jan 1;286(6358):16-8 [6401441.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Gut. 1989 Mar;30(3):333-8 [2707633.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] BMJ. 1994 Jan 1;308(6920):13-5 [8298344.001]
  • [Cites] Gut. 1994 Sep;35(9):1215-8 [7959226.001]
  • [Cites] J Clin Gastroenterol. 1995 Sep;21(2):123-9 [8583077.001]
  • [Cites] Gut. 1996 Apr;38(4):528-30 [8707082.001]
  • [Cites] Gastroenterology. 1998 Mar;114(3):471-81 [9496937.001]
  • [Cites] Gut. 2005 Jan;54(1):54-9 [15591504.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4 Suppl 1):S79-86 [15825131.001]
  • [Cites] CA Cancer J Clin. 2005 Nov-Dec;55(6):368-76 [16282281.001]
  • [Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):51-60 [16391371.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Feb;18(2):187-94 [16394801.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):315-9 [16527694.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Nov;4(11):1320-1 [17110301.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1981-2002 [17087937.001]
  • [Cites] Blood. 2007 Jan 15;109(2):412-21 [16973955.001]
  • [Cites] Br J Haematol. 2007 Jan;136(1):111-3 [17116129.001]
  • [Cites] Br J Haematol. 2007 Apr;137(2):170; author reply 171 [17391498.001]
  • [Cites] Aliment Pharmacol Ther. 2007 May 15;25(10):1237-45 [17451570.001]
  • [Cites] Gastroenterology. 2007 May;132(5):1902-11 [17484883.001]
  • [Cites] Dig Liver Dis. 2007 Jul;39(7):634-41 [17531561.001]
  • [Cites] Gut. 2007 Oct;56(10):1373-8 [17470479.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1731-43 [17960014.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Dec;5(12):1399-405, 1405.e1-2 [17967566.001]
  • [Cites] Scand J Gastroenterol. 2008;43(11):1322-8 [18618372.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2009 Jan;21(1):66-70 [19011576.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):91-8 [18950631.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):99-107; quiz 352-3 [18996383.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):81-90 [19014942.001]
  • [Cites] Gastroenterology. 2009 Jul;137(1):88-93 [19362553.001]
  • [Cites] Gut. 2010 Apr;59(4):547-57 [20332526.001]
  • [Cites] Blood. 2010 May 6;115(18):3664-70 [20197551.001]
  • [Cites] JAMA. 2002 Mar 20;287(11):1413-9 [11903028.001]
  • (PMID = 20851210.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK057892; United States / NIAID NIH HHS / AI / T32 AI007047; United States / NIDDK NIH HHS / DK / DK-57892; United States / NIAID NIH HHS / AI / T32 AI-07047
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS237618; NLM/ PMC3594736
  •  go-up   go-down


51. Belgaumi AF, Al-Kofide A, Sabbah R, Shalaby L: Precursor B-cell lymphoblastic lymphoma (PBLL) in children: pattern of presentation and outcome. J Egypt Natl Canc Inst; 2005 Mar;17(1):15-9
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor B-cell lymphoblastic lymphoma (PBLL) in children: pattern of presentation and outcome.
  • PURPOSE AND BACKGROUND: Precursor B-cell lymphoblastic lymphoma (PBLL) is a rare subtype of NHL seen primarily in children or young adults.
  • RESULTS: Twenty one patients were treated for lymphoblastic lymphoma, of which six had a precursor Bcell phenotype.
  • Four of the patients had limited stage disease (2 stage I and stage II), while 2 were stage IV.
  • Both patients with stage IV disease had CNS involvement with blasts in the CSF.
  • Five patients were treated according to B-cell NHL type protocols.
  • CONCLUSION: PBLL is a distinct B-cell NHL which involves extralymphatic sites, with particular predisposition for the upper aerodigestive tract.
  • Patients should not be treated on short intensive protocols used for other B-cell NHL but should receive treatment based on ALL protocols like those for treating T-cell LL.
  • [MeSH-major] B-Lymphocytes / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353078.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


52. Arcaini L, Burcheri S, Rossi A, Passamonti F, Paulli M, Boveri E, Brusamolino E, Orlandi E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT, Zaja F, Montanari F, Pascutto C, Morra E, Cortelazzo S, Lazzarino M: Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist; 2006 Mar;11(3):285-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination.
  • The aim of this study is to describe the clinical features and define the prognostic significance of disease dissemination in a large series of nongastric marginal-zone B-cell mucosa-associated lymphoid tissue (MALT) lymphomas.
  • We studied 208 patients with nongastric marginal-zone B-cell MALT lymphoma diagnosed and treated from 1991 to 2004.
  • On univariate analysis, the features significantly associated with longer EFS and OS times were the following: single MALT site involvement (OS), localized disease (EFS and OS), no nodal disease (EFS and OS), skin and orbit lymphoma (OS), and stage IV disease without bone marrow involvement (OS).
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549813.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Antineoplastic Agents
  •  go-up   go-down


53. Galicier L, Fieschi C, Borie R, Meignin V, Daniel MT, Gérard L, Oksenhendler E: Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood; 2007 Oct 15;110(8):2846-54
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study.
  • Prognosis of acquired immunodeficiency syndrome (AIDS)-related non-Hodgkin lymphoma has improved since the introduction of highly active antiretroviral therapy.
  • We have prospectively evaluated the LMB86 regimen in 63 human immunodeficiency virus (HIV)-infected patients with stage IV (BM and/or CNS involvement) BL consecutively recruited between November 1992 and January 2006.
  • At BL diagnosis, the median CD4 cell count was 239 x 10(6)/L (range, 16-1188 x 10(6)/L).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609431.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


54. Oh SY, Kim WS, Kim SJ, Kim JS, Kim SH, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Kim JG, Yang DH, Kang HJ, Choi CW, Park J, Choi YJ, Kim HJ, Kwon JH, Suh C, Kim HJ: Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases. Am J Hematol; 2009 Dec;84(12):826-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases.
  • Over its long survival duration, marginal zone B-cell lymphoma (MZL) routinely involves frequent relapses.
  • Of the 53 patients with Stage I or II at diagnosis, 42 patients (79.2%) evidenced locoregional recurrence.
  • In addition to the 39 patients initially in advanced Stage III or IV, a total of 50 patients were in advanced stage at relapse.
  • Among those patients with advanced stage at relapse, 44 patients were treated.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19890833.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Troutaud D, Petit B, Bellanger C, Marin B, Gourin-Chaury MP, Petit D, Olivrie A, Feuillard J, Jauberteau MO, Bordessoule D: Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk; 2010 Apr;10(2):118-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma.
  • BACKGROUND: To determine whether proapoptotic proteins were associated with clinicopathologic heterogeneity and influenced survival in patients with diffuse large B-cell lymphoma (DLBCL), we evaluated patterns of expression of the BCL-2 family member BAD, PP1alpha (the catalytic subunit of PP1 involved in activation of BAD), and apoptosis-inducing factor (AIF).
  • Lower BAD expression was shown to be significantly associated with advanced clinical stages (Ann Arbor stage III + IV and International Prognostic Index intermediate-high to high; P = .006 and P = .0008, respectively).
  • Finally, high AIF expression proved to be predictive of a longer overall survival in non-rituximab-treated patients.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / metabolism
  • [MeSH-minor] Antibodies, Monoclonal. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols. Apoptosis. Apoptosis Inducing Factor. B-Lymphocytes / chemistry. B-Lymphocytes / metabolism. B-Lymphocytes / pathology. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Prognosis. Rituximab. Stilbenes. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20371444.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Apoptosis Inducing Factor; 0 / Stilbenes; 25431-18-9 / benzoylamido-4'-aminostilbene-2,2'-disulfonate; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


56. Wada N, Ikeda J, Kohara M, Ogawa H, Hino M, Fukuhara S, Kanamaru A, Sugiyama H, Kanakura Y, Morii E, Aozasa K: Diffuse large B-cell lymphoma with a high number of epithelioid histiocytes (lymphoepithelioid B-cell lymphoma): a study of Osaka Lymphoma Study Group. Virchows Arch; 2009 Sep;455(3):285-93
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma with a high number of epithelioid histiocytes (lymphoepithelioid B-cell lymphoma): a study of Osaka Lymphoma Study Group.
  • The aim of this study was to clarify whether diffuse large B-cell lymphoma (DLBCL) with a high number of epithelioid histiocytes (DLBCL-EH) could have distinctive clinicopathological characteristics.
  • Stage of disease was I in five cases, II in three, III in nine, and IV in five.
  • [MeSH-major] Histiocytes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Leuk Lymphoma. 2007 Sep;48(9):1764-73 [17786712.001]
  • [Cites] Leuk Res. 2004 Mar;28(3):229-36 [14687617.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2765-3775 [19096012.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Histopathology. 2002 Jan;40(1):31-45 [11903596.001]
  • [Cites] Pediatr Blood Cancer. 2008 Oct;51(4):557-9 [18523988.001]
  • [Cites] Am J Surg Pathol. 1992 Apr;16(4):351-63 [1373580.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] J Clin Exp Hematop. 2007 Apr;47(1):23-6 [17510535.001]
  • [Cites] Eur J Haematol. 2007 Dec;79(6):501-7 [17986209.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1271-7 [12663714.001]
  • [Cites] Cancer. 1978 Feb;41(2):562-7 [630538.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Am J Clin Pathol. 1995 Jan;103(1):65-75 [7817948.001]
  • [Cites] Oncologist. 2006 Apr;11(4):384-92 [16614234.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • (PMID = 19727807.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


57. Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, Brusamolino E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT, Zaja F, Montanari F, Merli M, Pascutto C, Morra E, Cortelazzo S, Lazzarino M: Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol; 2007 Feb;18(2):346-50
MedlinePlus Health Information. consumer health - Hepatitis C.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT.
  • BACKGROUND: Hepatitis C virus (HCV) infection is frequently associated with B-cell non-Hodgkin's lymphomas.
  • METHODS: We retrospectively studied 172 patients with a histological diagnosis of marginal zone B-cell lymphoma of MALT, except for stomach, and with available HCV serology, among a series of 208 patients.
  • The majority of stage IV HCV-positive patients (71%) had a single MALT site with bone marrow involvement.
  • In multivariate analysis, advanced disease (stage III-IV) was associated with a poorer OS (P = 0.0001), irrespective of HCV serostatus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071937.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Biomarkers
  •  go-up   go-down


58. Hatef E, Roberts D, McLaughlin P, Pro B, Esmaeli B: Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma. Arch Ophthalmol; 2007 Dec;125(12):1663-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma.
  • OBJECTIVE: To determine the stage at initial examination and the prevalence of systemic involvement in patients with orbital and ocular adnexal lymphoma.
  • METHODS: The medical records of all patients with orbital and ocular adnexal lymphoma treated in a recent 7-year period were reviewed for stage at initial examination, highest stage during the follow-up period, and recurrence-free survival.
  • Nineteen patients had mucosa-associated lymphoid tissue, 9 had follicular, 9 had diffuse large-cell, 3 had mantle cell, 2 had small lymphocytic, and 1 had large T-cell lymphoma.
  • Lymphoma stage at diagnosis was IE in 18 patients, II in 6, and IV in 19.
  • Six of 19 patients with mucosa-associated lymphoid tissue, 7 of 9 patients with follicular, 6 of 9 patients with diffuse large-cell, and 3 of 3 patients with mantle cell lymphoma had non-stage IE disease at initial examination.
  • CONCLUSIONS: Extraorbital involvement is present at diagnosis in more than half of patients with orbital and ocular adnexal lymphoma and warrants extensive systemic workup at diagnosis, continued surveillance, and consideration of systemic therapy.
  • [MeSH-major] Conjunctival Neoplasms / pathology. Eyelid Neoplasms / pathology. Lymphoma / pathology. Orbital Neoplasms / pathology

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18071119.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Gallium Radioisotopes
  •  go-up   go-down


59. Saif MW, Khubchandani S, Walczak M: Secondary pancreatic involvement by a diffuse large B-cell lymphoma presenting as acute pancreatitis. World J Gastroenterol; 2007 Sep 28;13(36):4909-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary pancreatic involvement by a diffuse large B-cell lymphoma presenting as acute pancreatitis.
  • Diffuse large B-cell lymphoma is the most common type of non-Hodgkin's lymphoma.
  • However, a diffuse large B-cell lymphoma presenting as acute pancreatitis is rare.
  • Biopsy of the axillary mass revealed a large B-cell lymphoma.
  • The patient was classified as stage IV, based on the Ann Arbor Classification, and as having a high-risk lymphoma, based on the International Prognostic Index.
  • A literature search revealed only seven cases of primary involvement of the pancreas in B-cell lymphoma presenting as acute pancreatitis.
  • However, only one case of secondary pancreatic involvement by B-cell lymphoma presenting as acute pancreatitis has been published.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis / etiology


60. Hesseling P, Broadhead R, Mansvelt E, Louw M, Wessels G, Borgstein E, Schneider J, Molyneux E: The 2000 Burkitt lymphoma trial in Malawi. Pediatr Blood Cancer; 2005 Mar;44(3):245-50
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The 2000 Burkitt lymphoma trial in Malawi.
  • BACKGROUND: We previously reported 57% 12-month event free survival (EFS) in Malawian children with stage I to III Burkitt lymphoma (BL) with an intermediate dose chemotherapy protocol lasting 77 days.
  • This protocol was shortened to 42 days and evaluated in children with stage I to IV disease for EFS and toxicity.
  • A fine needle aspirate, bone marrow aspirate, cerebrospinal fluid cytology, haemoglobin (Hb), white cell count (WCC), malaria smear, ELISA for HIV, and abdominal ultrasound were performed routinely.
  • The first dose of chemotherapy (COP1) consisted of 300 mg cyclophosphamide (CPM), 1 mg vincristine, and 60 mg prednisone given on day 1 and followed by COP2 on day 8 (only for patients with larger tumour volumes, stage III or IV disease).
  • RESULTS: Forty-two patients, 30 boys and 12 girls median ages 6 and 7.5 years, respectively, had Murphy stage I(n5), II(n8), III(n21), and IV(n8) disease.
  • The projected EFS at 12 months is 50% in stage I, 50% in stage II, 24% in stage III, 25% in stage IV, and 33% for all patients.
  • [MeSH-major] Burkitt Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Malaria and HIV .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15547922.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


61. Kao SC, Kau HC, Tsai CC, Tsay SH, Yang CF, Wu JS, Hsu WM: Lacrimal gland extranodal marginal zone B-cell lymphoma of MALT-type. Am J Ophthalmol; 2007 Feb;143(2):311-316
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lacrimal gland extranodal marginal zone B-cell lymphoma of MALT-type.
  • PURPOSE: To evaluate the clinical features and outcome of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type (MALT lymphoma) in the lacrimal gland.
  • METHODS: A consecutive series of 13 histologically verified MALT lymphoma in the lacrimal gland at presentation was studied.
  • All patients had no prior lymphoma and initially presented as MALT lymphoma in the lacrimal gland.
  • Two patients had autoimmune disease, and both had Stage IV disease at presentation.
  • Patients with bilateral disease (61.5%) had a higher rate of advanced-stage disease and a poor outcome.
  • At the last follow-up, eight patients were free of disease, three were alive with disease, one died of sepsis as a complication of chemotherapy, and one died of lymphoma.
  • CONCLUSIONS: MALT lymphoma in the lacrimal gland has a high rate of extraorbital involvement and synchronous bilateral lacrimal gland involvement at presentation.
  • [MeSH-major] Eye Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology. Lymphoma, B-Cell, Marginal Zone / pathology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17184716.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Xu FP, Liu YH, Luo XL, Zhuang HG, Li L, Luo DL, Xu J, Zhang F, Zhang MH, Du X, Li WY: [Clinicopathologic significance of bcl-6 gene rearrangement and expression in three molecular subgroups of diffuse large B-cell lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2008 Jun;37(6):371-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic significance of bcl-6 gene rearrangement and expression in three molecular subgroups of diffuse large B-cell lymphoma].
  • OBJECTIVE: To investigate the role of bcl-6 gene rearrangement and bcl-6 expression in three molecular subgroups of diffuse large B-cell lymphoma (DLBCL) and its clinicopathological significance.
  • RESULTS: One hundred and forty nine of 163 cases were further classified into three molecular subgroups: 40 cases of germinal center B-cell-like (GCB) type, 75 cases of activated non-germinal center B-cell-like (ABC) type, 34 cases of Type 3.
  • Twenty-nine of 33 (87.9%) cases of DLBCL with bcl-6 gene rearrangement presented with advanced stage (Ann Arbor stage III/IV), which was higher than those without bcl-6 gene rearrangement (65/85, 76.5% , P=0.167).
  • [MeSH-major] Cyclin D3 / genetics. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-bcl-6 / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031715.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclin D3; 0 / Proto-Oncogene Proteins c-bcl-6
  •  go-up   go-down


63. Pisani F, Romano A, Anticoli Borza P, Marino M, Micheli A, Botti C, Petti MC: Diffuse large B-cell lymphoma involving the breast. A report of four cases. J Exp Clin Cancer Res; 2006 Jun;25(2):277-81
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma involving the breast. A report of four cases.
  • Non-Hodgkin lymphoma of the breast is an uncommon form of lymphoma occurring either primary disease (PBL) or part of systemic involvement.
  • We report the clinical outcome of 4 consecutive cases with CD20+ diffuse large B-cell lymphoma (DLBCL) of the breast, in the attempt to further clarify the management of this disease.
  • The median age was 53 years (39-61), stages were IIE (n=2), IIIE (n=1), and IV (n=1); IPI scores were 0 (n=2), 2 (n=2).
  • Two stage IIE patients received MACOP-B, radiation therapy was given to one of them and both achieved CR.
  • The stage IIIE patient treated with MACOP-B plus Rituximab was in PR at the beginning of the Rituximab and achieved CR at the end of the treatment.
  • The 61-year-old stage IV patient and bilateral involvement received P-VNBEC as first line treatment, achieving PR; she was then treated with 4 cycles of MACOP-B plus Rituximab obtaining CR.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16918141.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


64. Reichard KK, McKenna RW, Kroft SH: ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod Pathol; 2007 Mar;20(3):310-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature.
  • We report detailed clinical and pathologic features of four cases of anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma (ALK-DLBCL), a rare entity with only 29 currently reported cases.
  • After CHOP and radiotherapy, two stage I patients were free of disease at 58 and 36 months, whereas a stage IV patient was dead of disease at 22 months.
  • [MeSH-major] Lymphoma, B-Cell / enzymology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / enzymology. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277765.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


65. Beltran B, Castillo J, Salas R, Quiñones P, Morales D, Hurtado F, Riva L, Winer E: ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol; 2009;2:11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature.
  • BACKGROUND: Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma (ALK-DLBCL) is a rare lymphoma with several clinicopathological differences from ALK-positive anaplastic large cell lymphoma (ALCL).
  • Stages were I (n = 1), II (n = 1), III (n = 1) and IV (n = 1).
  • The survival for the patients with stage I, II, III and IV were 13, 62, 72 and 11 months, respectively.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / metabolism. Protein-Tyrosine Kinases / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2009 Jan;40(1):75-82 [18755494.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):804-9 [18756521.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Am J Clin Pathol. 2001 Mar;115(3):396-403 [11242796.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):828-32 [12920229.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2638-41 [12750159.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2568-73 [12763927.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2642-4 [12816858.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1285-8 [15492998.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1483-90 [9057627.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] Pol J Pathol. 2005;56(1):37-45 [15921012.001]
  • [Cites] Curr Oncol Rep. 2005 Sep;7(5):357-63 [16091196.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1839-40 [16107887.001]
  • [Cites] Pediatr Blood Cancer. 2006 Mar;46(3):390-1 [16086416.001]
  • [Cites] Rinsho Ketsueki. 2005 Jul;46(7):501-6 [16440742.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):649-53 [15852431.001]
  • [Cites] Nat Rev Cancer. 2006 Jul;6(7):493-505 [16794633.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2006 Sep;35(9):529-34 [17134546.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):310-9 [17277765.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):940-5 [17509395.001]
  • [Cites] Eur J Haematol. 2007 Aug;79(2):166-9 [17635242.001]
  • [Cites] Cancer. 2007 Aug 25;111(4):224-33 [17554754.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2573-80 [18089849.001]
  • [Cites] J Cell Mol Med. 2008 Jan-Feb;12(1):126-44 [18039352.001]
  • [Cites] Korean J Lab Med. 2008 Apr;28(2):89-94 [18458503.001]
  • [Cites] Biochem J. 2008 Jun 15;412(3):415-23 [18498251.001]
  • [Cites] Hematol Oncol. 2008 Jun;26(2):108-13 [18220322.001]
  • (PMID = 19250532.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Interferon Regulatory Factors; 0 / interferon regulatory factor-4; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Number-of-references] 39
  • [Other-IDs] NLM/ PMC2651189
  •  go-up   go-down


66. Ohshima R, Tomita N, Motohashi K, Ieda A, Hyou R, Fujisawa S, Fujita H, Sakai R, Koharazawa H, Kuwabara H, Kanamori H, Ishigatsubo Y: [Clinical course of 8 patients with intravascular large B-cell lymphoma diagnosed while alive]. Rinsho Ketsueki; 2005 Jun;46(6):453-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical course of 8 patients with intravascular large B-cell lymphoma diagnosed while alive].
  • We retrospectively evaluated the diagnosis and clinical courses of 8 patients with intravascular large B-cell lymphoma (IVL) diagnosed while they were alive.
  • All patients were in clinical stage IV with B symptoms and 4 patients showed performance status 4.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Vascular Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447727.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 17
  •  go-up   go-down


67. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM: Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol; 2005 Aug 1;23(22):5027-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
  • PURPOSE: For more than two decades, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been the standard therapy for diffuse large B-cell lymphoma (DLBCL).
  • METHODS: We compared outcomes during a 3-year period; 18 months before (prerituximab) and 18 months after (postrituximab) institution of a policy recommending the combination of CHOP and rituximab for all patients with newly diagnosed advanced-stage (stage III or IV or stage I or II with "B" symptoms or bulky [> 10 cm] disease) DLBCL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15955905.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


68. Leopardo D, Di Lorenzo G, De Renzo A, Federico P, Luponio S, Buonerba C, Matano E, Merola G, Imbimbo M, Montesarchio E, Rea A, Merola MC, De Placido S, Palmieri G: Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. World J Gastroenterol; 2010 May 28;16(20):2526-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of rituximab in gastric diffuse large B cell lymphoma patients.
  • AIM: To evaluate retrospectively the efficacy of rituximab plus chemotherapy in gastric diffuse large B cell lymphoma (DLBCL).
  • Patients were selected by stage (I-IV, Lugano staging system), European Cooperative Oncology Group performance status (0-2) and treatment strategies.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Stomach Neoplasms / drug therapy


69. Qi SN, Li YX, Wang H, Wang WH, Jin J, Song YW, Wang SL, Liu YP, Zhou LQ, Yu ZH: Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation. Cancer; 2009 Nov 1;115(21):4980-9
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation.
  • BACKGROUND: : The objective of this study was to compare the clinical features and prognosis of patients with diffuse large B-cell lymphoma (DLBCL) of Waldeyer ring (WR-DLBCL) and patients with lymph node DLBCL (N-DLBCL).
  • There were 57 patients with stage I disease, 83 patients with stage II disease, 26 patients with stage III disease, and 15 patients with stage IV disease.
  • Compared with patients who had N-DLBCL, patients who had WR-DLBCL presented with more stage II disease and lower tumor burdens.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoid Tissue / pathology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19634158.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Sun XF, Zhen ZJ, Lui DG, Xia Y, He YJ, Wang ZH, Lin JY, Guan ZZ: Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol. Eur J Haematol; 2006 Nov;77(5):365-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol.
  • OBJECTIVES: This study was designed to evaluate the efficacy and toxicity of the modified B-Non-Hodgkin's Lymphoma (NHL)-Berlin-Frankfurt-Münster (BFM)-90-based protocol in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma.
  • The patients were stratified by risk factors (stage, LDH level and chemotherapy response).
  • Of these patients, 22 (40%) had Burkitt's lymphoma (BKL), 22 (40%) had diffuse large B-cell lymphoma (DLBL) and 11 (20%) had anaplastic large T-cell lymphoma (ALCL).
  • At a median follow up of 24 months, the event free survival (EFS) for all patients was 85% +/- 5% with 100% for group R1, 84% +/- 7% for group R2 and 72% +/- 13% for group R3, and most notably, 80% +/- 6% for stage III/IV at diagnosis.
  • CONCLUSIONS: This modified NHL-BFM-90 protocol is very effective for Chinese children and adolescents with BKL and large cell lymphomas, and represented an increase in the cure rates in childhood NHL in China.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, T-Cell / drug therapy

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879606.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


71. Griffiths R, Gleeson M, Knopf K, Danese M: Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL). BMC Cancer; 2010;10:625
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL).
  • BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) comprises 31% of lymphomas in the United States.
  • Although it is an aggressive type of lymphoma, 40% to 50% of patients are cured with treatment.
  • Outcomes variables in the survival analysis were all-cause mortality, non-Hodgkin's lymphoma (NHL) mortality, and other/unknown cause mortality.
  • Median age at diagnosis was 77 years, 54% were female, 88% were white, and 43% had Stage III or IV disease at diagnosis.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Cancer. 2008 Dec 1;113(11):3231-41 [18937267.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] J Clin Epidemiol. 1994 Mar;47(3):249-60 [8138835.001]
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Semin Hematol. 2006 Oct;43(4):213-20 [17027655.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):171-80 [18040998.001]
  • [Cites] BMC Cancer. 2007;7:193 [17939875.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • (PMID = 21073707.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2995801
  •  go-up   go-down


72. Linderoth J, Ehinger M, Akerman M, Cavallin-Ståhl E, Enblad G, Erlanson M, Jerkeman M: Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma. Eur J Haematol; 2007 Aug;79(2):146-9
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma.
  • OBJECTIVE: In this study, our aim was to investigate how different immunohistochemical techniques may influence the result of BCL6 positivity and categorization in germinal center (GC) and non-GC derived diffuse large B-cell lymphoma (DLBCL), as it has been proposed that classification of DLBCL according to cell-of-origin by immunohistochemistry may be performed as a routine procedure in the diagnostic work-up.
  • METHODS: Tumor specimens from 122 patients with de novo stage II-IV disease, adequately treated with anthracycline-containing chemotherapy regimens were collected.
  • Consequently, the results from categorization into GC and non-GC DLBCL differed considerably by use of the two methods, and resulted in very different outcome in terms of overall survival.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Proto-Oncogene Proteins c-bcl-6 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17635238.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-6; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


73. Rasmussen P, Sjö LD, Prause JU, Ralfkiaer E, Heegaard S: Mantle cell lymphoma in the orbital and adnexal region. Br J Ophthalmol; 2009 Aug;93(8):1047-51
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma in the orbital and adnexal region.
  • AIMS: To characterise clinicopathological features of mantle cell lymphoma (MCL) in the orbital and adnexal region.
  • METHODS: Data on lymphoid lesions were retrieved searching the Danish Ocular Lymphoma Database 1980-2005.
  • RESULTS: Twenty-one patients with MCL in the orbital and adnexal region were identified comprising 9% (21/230) of all lymphoma in the ocular region.
  • All but two presented in stage III/IV.
  • Most patients presented with stage IV disease and had multiple relapses and short survival time.
  • [MeSH-major] Eye Neoplasms / pathology. Lymphoma, Mantle-Cell / pathology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Genetic Alliance. consumer health - Orbital lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19429588.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


74. Linderoth J, Edén P, Ehinger M, Valcich J, Jerkeman M, Bendahl PO, Berglund M, Enblad G, Erlanson M, Roos G, Cavallin-Ståhl E: Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma. Br J Haematol; 2008 May;141(4):423-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma.
  • In order to identify genes associated with primary chemotherapy-resistance, gene expression profiles (GEP) in tumour tissue from 37 patients with de novo diffuse large B-cell lymphoma (DLBCL), stage II-IV, either in continuous complete remission (n = 24) or with progressive disease during primary treatment (n = 13), were examined using spotted 55K oligonucleotide arrays.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Gene Expression Profiling / methods. Genes, Neoplasm. Lymphoma, Large B-Cell, Diffuse / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18419622.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Neoplasm
  •  go-up   go-down


75. Ahmad N, Zaidi A, Badar F, Maaz AU, Akram MS: Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country. Asia Pac J Clin Oncol; 2010 Mar;6(1):49-56

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country.
  • AIM: To analyze the clinical characteristics of B-cell non-Hodgkin's lymphoma (NHL) patients and the therapeutic efficacy of French-American-British Lymphoma Malins de Burkitt 96 and the recent United Kingdom Children's Cancer Study Group B-cell NHL guidelines in the tertiary care hospital of a developing country.
  • METHODS: Patients aged < or =18 years registered at our hospital between January 1995 and December 2006 with histologically proved B-Cell NHL were selected for retrospective analysis.
  • Of these 95 had Burkitt's lymphoma, 22 diffuse large B-cell lymphoma and five had B-cell NHL not otherwise specified.
  • A total of 37 had uric acid >10 mg/dl and 55 had a lactate dehydrogenase level >500; 73 had stage III and 31 had stage IV while only four presented at stage I and 14 at stage II.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Practice Guidelines as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398038.001).
  • [ISSN] 1743-7563
  • [Journal-full-title] Asia-Pacific journal of clinical oncology
  • [ISO-abbreviation] Asia Pac J Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


76. Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS: Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol; 2010 Sep 20;28(27):4170-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
  • PURPOSE: The current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
  • Variables including age, sex, Ann Arbor disease stage, bulky disease status, standardized uptake values (SUVs) on positron emission tomography (PET), International Prognostic Index (IPI), and Ki67 staining (proliferation).
  • RESULTS: Of 469 patients, 190 (40.5%) had stage I or II disease and 279 (59.5%) had stage III or IV disease, 327 (70%) had at least six cycles of R-CHOP, and 142 (30.2%) had involved-field RT (dose, 30 to 39.6 Gy) after complete response to chemotherapy.
  • Matched-pair analyses of patients who received six to eight cycles of R-CHOP with stage I or II disease (44 pairs) and all stages (74 pairs) indicated that RT improved OS (hazard ratio [HR], 0.52 and 0.29, respectively) and PFS (HR, 0.45 and 0.24, respectively) compared with no RT.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Prednisone / administration & dosage. Vincristine / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Cell Proliferation. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Male. Matched-Pair Analysis. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Rituximab. Survival Analysis. Texas. Time Factors. Treatment Outcome. Young Adult


77. Liu YH, Zhuang HG, Lin HL, Wu QL, Luo DL, Luo XL: [T-cell/histiocyte-rich B-cell lymphoma: histology, immunophenotype and differential diagnosis]. Zhonghua Bing Li Xue Za Zhi; 2005 Dec;34(12):771-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [T-cell/histiocyte-rich B-cell lymphoma: histology, immunophenotype and differential diagnosis].
  • OBJECTIVE: To study the histology, immunophenotype and differential diagnosis of T-cell/histiocyte-rich B-cell lymphoma (TCRBCL).
  • METHODS: A review of 245 cases of so-called Hodgkin lymphoma diagnosed during the period from 1980 to 2000 in 3 hospitals in Guangzhou, 8 cases were reclassified as TCRBCL, according to the 2001 World Health Organization classification of lymphoid neoplasms.
  • Immunohistochemical studies were performed on paraffin-embedded tissue by SP technique in order to study the immunophenotype of the large neoplastic cells (CD20, CD79a, CD3, CD45RO, CD15, CD30, CD10, bcl-6 and EMA) and background non-neoplastic cells (CD3, CD8, CD20, CD45RO, CD79a, CD57, CD68, CD21, CD35, cyclin D1, TIA-1).
  • On presentation, 3 cases belonged to stage II, 10 cases stage III and 3 cases stage IV.
  • The histiocytic cells were CD68-positive; and CD21 and CD35-positive follicular dendritic cell meshworks were absent.
  • CONCLUSIONS: TCRBCL is a rare subtype of lymphoma, with distinctive histology and immunophenotype.
  • The above features are helpful in delineating this entity from Hodgkin lymphoma, reactive lymphoid hyperplasia and lymphomatoid granulomatosis.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / metabolism. Antigens, CD79 / metabolism. Child. Diagnosis, Differential. Female. Hodgkin Disease / pathology. Humans. Immunophenotyping. Male. Middle Aged. Mucin-1 / metabolism. Neoplasm Staging. Retrospective Studies

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16545182.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD79; 0 / Mucin-1
  •  go-up   go-down


78. Choi JW, An JS, Lee JH, Lee ES, Kim KH, Kim YS: Clinicopathologic implications of tissue inhibitor of metalloproteinase-1-positive diffuse large B-cell lymphoma. Mod Pathol; 2006 Jul;19(7):963-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic implications of tissue inhibitor of metalloproteinase-1-positive diffuse large B-cell lymphoma.
  • The expression of TIMP-1 is known to be correlated with a subset of non-Hodgkin lymphoma at the mRNA level, and Epstein-Barr virus infection in vitro.
  • To characterize TIMP-1(+) diffuse large B-cell lymphoma, TIMP-1 expression was investigated in tissue microarrays from 182 cases of de novo diffuse large B-cell lymphoma and compared with prognostic factors, immunophenotypes, and Epstein-Barr virus infection status.
  • TIMP-1 was expressed not only in tumor cells themselves, in 14 of 182 cases (8%), designated as TIMP-1(+) diffuse large B-cell lymphoma, but also in stromal cells like fibroblasts and endothelial cells.
  • In multivariate analysis, TIMP-1(+) diffuse large B-cell lymphoma (n=14) was associated with unfavorable outcomes compared to TIMP-1(-) diffuse large B-cell lymphoma (n=168) (odds ratio=2.5, P=0.049).
  • Together with TIMP-1 expression, age (greater than 60 years), the presence of B-symptoms, abnormal lactate dehydrogenase level, or more advanced stage (III/IV) was correlated with a poor overall survival.
  • However, TIMP-1 expression in diffuse large B-cell lymphoma was not correlated with other prognostic factors including: clinical stage, international prognostic index score, and nongerminal center B-cell phenotype, as well as Epstein-Barr virus infection.
  • Our results suggest that TIMP-1 expression may be an independent negative prognostic factor in patients with diffuse large B-cell lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Tissue Inhibitor of Metalloproteinase-1 / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648868.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


79. Chen SW, Chang ST, Lu CL, Hwang WS, Tsao CJ, Huang WT, Chang KY, Chuang SS: Upper aerodigestive tract lymphoma in Taiwan. J Clin Pathol; 2010 Oct;63(10):888-93
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper aerodigestive tract lymphoma in Taiwan.
  • AIM: To better understand the spectrum of primary lymphomas in the upper aerodigestive tract, a common site of extranodal lymphoma.
  • MATERIALS AND METHODS: Lymphoma cases diagnosed at an institution in southern Taiwan from 1992 to 2007 were retrospectively studied with pathology and history review, immunohistochemistry, in situ hybridisation for Epstein-Barr virus (EBER-ISH), and statistical analysis.
  • Phenotypically, there were 45 (64%) B cell and 25 (36%) T cell or extranodal natural killer (NK)/T cell lymphoma (ENKL) including 42 (60%) diffuse large B cell lymphomas (DLBCLs), 22 (31%) ENKLs, three unspecified peripheral T cell lymphomas, two follicular lymphomas and one Burkitt lymphoma.
  • The 5-year overall survival for all patients was 56.3% with B and T or NK/T cell lymphomas at 66.0% and 40.6%, respectively.
  • Univariate analysis revealed that sinonasal presentation, T or NK/T cell phenotype, raised lactate dehydrogenase (LDH) activity, and Ann Arbor stage III/IV diseases were associated with prognostically significant higher hazard ratio (HR) of lymphoma-related death.
  • CONCLUSIONS: Only a limited number of lymphoma entities occurred primarily in this anatomical region.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Child. Epidemiologic Methods. Epstein-Barr Virus Infections / complications. Female. Humans. L-Lactate Dehydrogenase / blood. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Lymphoma, B-Cell / virology. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / therapy. Lymphoma, T-Cell / virology. Male. Middle Aged. Mouth Neoplasms / pathology. Mouth Neoplasms / therapy. Mouth Neoplasms / virology. Neoplasm Staging. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876320.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


80. Wang F, Xu RH, Luo HY, Zhang DS, Jiang WQ, Huang HQ, Sun XF, Xia ZJ, Guan ZZ: Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer; 2008;8:115
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma.
  • BACKGROUND: Hepatitis B virus (HBV) infection in diffuse large B-cell lymphoma (DLBCL) patients is a common complication in China.
  • RESULTS: Compared with the HBsAg-negative group, the HBsAg-positive DLBCL group displayed a younger median onset age (46 year vs 51), more advanced stage at grade III/IV (58% vs 42%, p = 0.016), and more frequent hepatic dysfunction before (21% vs 5.5%, p < 0.001) and during (49.4% vs 16.6%, p < 0.001) chemotherapy.
  • In the HBsAg-positive DLBCL group, the poor prognostic factors were advanced stage (p < 0.001) and hepatic dysfunction during chemotherapy (p = 0.02).
  • CONCLUSION: Compared with HBsAg-negative patients, the HBsAg-positive DLBCL patients had earlier onset and more advanced stage.
  • The disease stage and hepatic dysfunction during chemotherapy and were two significant prognostic factors in the HBsAg-positive DLBCL patients.
  • [MeSH-major] Hepatitis B / diagnosis. Hepatitis B / epidemiology. Lymphoma, B-Cell / epidemiology

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Eur J Haematol. 2007 Aug;79(2):132-7 [17635237.001]
  • [Cites] J Med Virol. 2000 Nov;62(3):299-307 [11055239.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Feb;16(2):215-9 [11207904.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2927-32 [11753968.001]
  • [Cites] Blood. 2002 Jan 15;99(2):724-5 [11799967.001]
  • [Cites] Lancet Oncol. 2002 Jun;3(6):333-40 [12107020.001]
  • [Cites] J Med Virol. 2002 Jul;67(3):447-50 [12116043.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2257-9 [12200395.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1884-6 [12200717.001]
  • [Cites] Hematol J. 2003;4(2):159-62 [12750737.001]
  • [Cites] Hepatology. 2003 Jun;37(6):1320-8 [12774010.001]
  • [Cites] Leuk Lymphoma. 2003 May;44(5):759-66 [12802911.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):927-34 [14990649.001]
  • [Cites] Ann Hematol. 2004 May;83(5):270-5 [15060745.001]
  • [Cites] Gastroenterology. 1991 Jan;100(1):182-8 [1983820.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1001-7 [7977632.001]
  • [Cites] Lancet. 1995 Jun 3;345(8962):1406-7 [7539089.001]
  • [Cites] N Engl J Med. 1995 Dec 21;333(25):1657-61 [7477217.001]
  • [Cites] Haematologica. 1997 Jan-Feb;82(1):38-42 [9107080.001]
  • [Cites] Ann Hematol. 2004 Dec;83(12):769-74 [15338194.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2616-7 [15746088.001]
  • [Cites] Expert Opin Drug Saf. 2005 May;4(3):599-608 [15934864.001]
  • [Cites] J Infect Chemother. 2005 Aug;11(4):189-91 [16133710.001]
  • [Cites] World J Gastroenterol. 2005 Sep 14;11(34):5283-8 [16149133.001]
  • [Cites] BMC Cancer. 2006;6:3 [16396674.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1320-5 [16470607.001]
  • [Cites] Haematologica. 2006 Apr;91(4):554-7 [16585021.001]
  • [Cites] Ann Oncol. 2006 Sep;17(9):1434-40 [16766591.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1053-6 [17034541.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1360-4 [17326056.001]
  • [Cites] J Med Virol. 2000 Mar;60(3):249-55 [10630955.001]
  • (PMID = 18433487.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens
  • [Other-IDs] NLM/ PMC2377276
  •  go-up   go-down


81. Chen DG, Yang Y, Pan CZ: [Primary mediastinal large B-cell lymphoma:a report of 24 cases with literature review]. Ai Zheng; 2008 Feb;27(2):187-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary mediastinal large B-cell lymphoma:a report of 24 cases with literature review].
  • BACKGROUND & OBJECTIVE: Primary mediastinal large B-cell lymphoma (PMBCL) is an uncommon subtybe of diffuse large B-cell lymphoma (DLBCL).
  • RESULTS: Of the 24 patients, 16 were men and 8 were women, aged from 12 to 81; 20 were at stage I-II, 1 at stage III, and 3 at stage IV; 13 had bulk disease; 10 had superior vena cava syndrome; 14 had contiguous infiltration; 15 had lacate dehydrogenase elevation; 11 received chemoradiotherapy, 10 received chemotherapy alone, and 3 received radiotherapy alone; 10 achieved complete remission (CR) after scheduled treatment, 12 achieved partial remission (PR), 1 had stable disease and 1 had progressive disease.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / therapy. Mediastinal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18279619.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 14
  •  go-up   go-down


82. Parvez T, Behani A, Ali A: Primary gastric lymphoma. J Coll Physicians Surg Pak; 2007 Jan;17(1):36-40
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric lymphoma.
  • OBJECTIVE: To evaluate the clinico-pathological status of Primary Gastric Lymphoma (PGL) at presentation in King Fahad Hospital, Madina Munawra, Kingdom of Saudi Arabia (KSA).
  • RESULTS: All cases were Non-Hodgkin Lymphoma (NHL).
  • There were 10 (45%) patients with stage II, and 6 (27%) patients each with stage III and IV diseases.
  • Diffuse large cell lymphoma was found in 12 (55%), poorly differentiated lymphoma in 3 (14%) and diffuse mixed in 7 (32%).
  • CONCLUSION: PGL is usually of NHL type, presenting in the sixth decade, and can be successfully treated with both surgery and chemotherapy when patients presented at stage II.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204218.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


83. Sun XF, Zhen ZJ, Xiang XJ, Ling JY, Peng RJ, Xia Y, Zheng L, Luo WB, Lin H, Guan ZZ: [Efficacy of modified B-NHL-BFM-90 protocol on anaplastic T-cell lymphoma in children and adolescents]. Ai Zheng; 2009 May;28(5):506-10
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of modified B-NHL-BFM-90 protocol on anaplastic T-cell lymphoma in children and adolescents].
  • BACKGROUND AND OBJECTIVE: Anaplastic T-cell lymphoma in children and adolescents is an aggressive malignant non-Hodgkin's lymphoma (NHL).
  • This study was to evaluate the efficacy of modified B-NHL-BFM-90 protocol on anaplastic T-cell lymphoma in children and adolescents.
  • METHODS: From October 2002 to January 2008, 18 untreated anaplastic T-cell lymphoma patients aged less than 16 years were enrolled, and treated with modified B-NHL-BFM-90 protocol including cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, HD-methotrexate, vindesine, dexamethasone, cytarabine/HD-cytarabine.
  • The 3-year event-free survival (EFS) rates were (87.4+/-8.4)% for all patients, 100% for stage II patients, and (85.1+/-9.7)% for stage III/IV patients; 100% for low risk group, (88.9+/-10.5)% for moderate risk group, and (80.0+/-17.9)% for high risk group.
  • One patient with stage IV disease received autologous peripheral blood stem cell transplantation (PBSCT) after CR and was still alive.
  • CONCLUSIONS: Modified B-NHL-BFM-90 protocol, with tolerable toxicity, is an effective treatment regimen for anaplastic T-cell lymphoma in children and adolescents.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large-Cell, Anaplastic / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. L-Lactate Dehydrogenase / blood. Leukopenia / chemically induced. Male. Methotrexate / administration & dosage. Neoplasm Staging. Remission Induction. Stem Cell Transplantation. Thrombocytopenia / chemically induced. Vincristine / administration & dosage. Vindesine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624879.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; RSA8KO39WH / Vindesine; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


84. Wada H, Sase T, Yamaguchi M: Hypercoagulant states in malignant lymphoma. Exp Oncol; 2005 Sep;27(3):179-85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypercoagulant states in malignant lymphoma.
  • The incidence of severe complications, such as disseminated intravascular coagulation (DIC) in malignant lymphoma, differs between clinical stages and histological types of the disease, but they occur frequently in stage IV or natural killer (NK) cell lymphoma.
  • Patients with stage IV or NK cell lymphoma exhibit abnormal thrombotic and hemostatic states.
  • One of the mechanisms in DIC might involve elevated cytokine expression by lymphoma cells stimulating the expression of tissue factor (TF) in blood cells or surrounding tissue.
  • During chemotherapy for lymphoma, the white blood cell count was significantly reduced at days 1 and 3, but significantly increased at days 7 and 9.
  • [MeSH-major] Disseminated Intravascular Coagulation / etiology. Disseminated Intravascular Coagulation / physiopathology. Lymphoma, Non-Hodgkin / complications

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244577.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Cytokines; 0 / RNA, Messenger; 9007-41-4 / C-Reactive Protein; 9035-58-9 / Thromboplastin; EC 3.4.21.37 / Leukocyte Elastase
  • [Number-of-references] 47
  •  go-up   go-down


85. Sun XF, Liu DG, Zhen ZJ, Chen XQ, Xia Y, Wang ZH, He YJ, Guan ZG: [Efficacy of short-term and intensive chemotherapy for the treatment of childhood and adolescent B cell non-Hodgkin's lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2005 Oct;26(10):581-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of short-term and intensive chemotherapy for the treatment of childhood and adolescent B cell non-Hodgkin's lymphoma].
  • OBJECTIVES: To evaluate the efficacy and toxicity of the B-NHL-BFM-90 protocol in the treatment of Chinese childhood and adolescent B-cell non-Hodgkin's lymphomas (B-NHL).
  • Of them 18 cases were Burkitt's lymphoma, 16 diffuse large B cell lymphoma and 8 anaplastic lymphoma.
  • There were 10 cases in stage II and 32 in stage III/IV.
  • Of the 5 PR patients, I received autologous hematopoietic stem cell transplantation, 3 received radiotherapy for residual disease and 1 just under watching.
  • 24%, being 100% for stage II and 80.95% for stage III/IV.
  • CONCLUSION: Short term and intensive chemotherapy can improves the efficacy and survival rate of childhood and adolescent B-NHL, especially for advanced stage patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16532964.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


86. Eissa LA, Esmaeel MI: Relevance of some serum biomarkers (E cadherin, GAGs & MDA in patients with diffuse large B-cell lymphoma. Pak J Pharm Sci; 2008 Jan;21(1):29-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relevance of some serum biomarkers (E cadherin, GAGs & MDA in patients with diffuse large B-cell lymphoma.
  • This study aimed to estimate the pretreatment serum levels of SVE-Cadherin, glycosaminoglycams (GAGs) and malondialdehyde (MDA) in order to evaluate their prognostic significance and their role in monitoring tumor response and overall-survival in Non Hodgkin lymphoma (DLCL) patients.
  • Also the work aimed to investigate the relationship between levels of these biochemical markers with LDH level, ESR and tumor stage.
  • For this purpose pretreatment serum levels of these biochemical markers were evaluated in 40 newly diagnosed patients with non-Hodgkin lymphoma (Diffuse large cell type) and studied in relation to expression in healthy control.
  • However, higher level of SVE-Cadherin was found in stage II, III of the disease as compared to stage IV disease but with no statistical significance.
  • Low level of SVE-Cadherin in stage IV participates in the invasiveness and metastasis of the disease.
  • [MeSH-major] Biomarkers, Tumor / blood. Cadherins / blood. Glycosaminoglycans / blood. Lymphoma, Large B-Cell, Diffuse / blood. Malondialdehyde / blood

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166516.001).
  • [ISSN] 1011-601X
  • [Journal-full-title] Pakistan journal of pharmaceutical sciences
  • [ISO-abbreviation] Pak J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Glycosaminoglycans; 4Y8F71G49Q / Malondialdehyde
  •  go-up   go-down


87. Knight C, Maciver F: The cost-effectiveness of rituximab in non-Hodgkin's lymphoma. Expert Rev Pharmacoecon Outcomes Res; 2007 Aug;7(4):319-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cost-effectiveness of rituximab in non-Hodgkin's lymphoma.
  • Rituximab is indicated: as the first-line treatment of diffuse-large B-cell non-Hodgkin's lymphoma (NHL) in combination with cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP); as the first-line treatment of stage III-IV follicular NHL in combination with cyclophosphamide, vincristine and prednisolone (CVP); for the treatment of patients with stage III-IV follicular lymphoma who are chemoresistant or in their second or subsequent relapse after chemotherapy; and as maintenance therapy for patients with relapsed/refractory follicular lymphoma responding to induction therapy with chemotherapy with or without rituximab.
  • The conclusion of these analyses is that rituximab, used both as monotherapy and in combination with chemotherapy, is a cost-effective intervention in the most common forms of NHL, diffuse large B-cell lymphoma and follicular NHL.
  • If it has the same clinical success in these trials as it has had in diffuse large B-cell lymphoma and follicular lymphoma, then it is possible that within a few years rituximab could play a key role in treating patients in all forms of NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20528413.001).
  • [ISSN] 1744-8379
  • [Journal-full-title] Expert review of pharmacoeconomics & outcomes research
  • [ISO-abbreviation] Expert Rev Pharmacoecon Outcomes Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


88. Traverse-Glehen A, Felman P, Callet-Bauchu E, Gazzo S, Baseggio L, Bryon PA, Thieblemont C, Coiffier B, Salles G, Berger F: A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology; 2006 Jan;48(2):162-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases.
  • AIMS: To report the clinicopathological findings of 21 cases of primary nodal marginal zone B-cell lymphoma (NMZL).
  • NMZL is a recently characterized lymphoma and few series have been published.
  • METHODS AND RESULTS: The clinical data were characteristic of a disseminated disease at presentation: presence of peripheral and abdominal lymph nodes, bone marrow involvement (62%), disease stage III and IV (76%), elevated lactate dehydrogenase (LDH) (48%).
  • Morphological features were heterogeneous and there were some differences compared with other marginal zone B-cell lymphomas (MZL).
  • Pure monocytoid B-cell lymphomas were rare (10%) but a minor component of monocytoid B cell was observed more frequently (23%).
  • [MeSH-major] Lymphoma, B-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405665.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


89. Yin HF, Li T: [Comparative study of heterogeneity of extranodal and nodal diffuse large B cell lymphoma]. Beijing Da Xue Xue Bao; 2007 Apr 18;39(2):158-62
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative study of heterogeneity of extranodal and nodal diffuse large B cell lymphoma].
  • OBJECTIVE: Primary nodal and extranodal diffuse large B-cell lymphoma (DLBCL) were investigated for the heterogeneity of histopathology and immunophenotype, and their relation to clinical stage, comparatively.
  • Whether E2F1 can be used as a germinal center B cell (GCB) DLBCL marker was also discussed.
  • RESULTS: Histopathologic morphology presented as: centroblastic (CB,88.8%, 87/98), immunoblastic (IB,5.1%, 5/98), anaplastic (ALCL,3.1%, 3/98), and T cell rich B cell lymphoma (TCRBCL,3.1%, 3/98).
  • The rate of Stage I/ II in GCB DLBCL (74.2%) were higher than in non-GCB DLBCL (50.7%, P=0.029).
  • The CD10 positive rates were 36.8% and 17.1% in Stages I/II and III/IV, respectively, and had significant differences (P=0.033).
  • The positive rates of E2F1 were 38.8% and 16.5% in GCB and non-GCB DLBCL, respectively, and had significant differences (P=0.016).
  • The prognosis of GCB DLBCL is better than that of non-GCB DLBCL.
  • [MeSH-major] Biomarkers, Tumor / analysis. Gastrointestinal Neoplasms / pathology. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440591.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / E2F1 Transcription Factor; 0 / E2F1 protein, human; 0 / Interferon Regulatory Factors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


90. Khera R, Jain S, Kumar L, Thulkar S, Vijayraghwan M, Dawar R: Diffuse large B-cell lymphoma: experience from a tertiary care center in North India. Med Oncol; 2010 Jun;27(2):310-8
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma: experience from a tertiary care center in North India.
  • Limited information is available from developing countries regarding clinico-pathological presentation of diffuse large B-cell lymphoma (DLBCL).
  • We undertook a retrospective case record study to determine the clinico-laboratory characteristics, treatment outcomes, and prognostic factors for DLBCL and additionally analyzed percentage distribution and patient characteristics for other major subtypes of non-Hodgkin's lymphoma (NHL).
  • A total of 49.3% of patients had Ann Arbor Stage IV disease.
  • [MeSH-major] Cancer Care Facilities. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Clin Radiol. 2008 Feb;63(2):125-35 [18194687.001]
  • [Cites] J Clin Pathol. 2006 Jan;59(1):48-55 [16394280.001]
  • [Cites] Cancer. 1992 Aug 15;70(4):840-9 [1643616.001]
  • [Cites] Eur J Haematol. 2008 Dec;81(6):448-53 [18691256.001]
  • [Cites] Br J Cancer. 1989 Feb;59(2):276-82 [2930692.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1813-9 [8859197.001]
  • [Cites] J Med Assoc Thai. 1980 Apr;63(4):181-91 [7381353.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):972-7 [4016691.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Oct;5(5):983-1001 [1938764.001]
  • [Cites] Leuk Res. 1985;9(6):799-802 [4010329.001]
  • [Cites] Arch Pathol Lab Med. 2008 Jan;132(1):118-24 [18181663.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):1-12 [15480663.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1993 Mar;15(2):86-90 [8223131.001]
  • [Cites] Pathol Int. 2000 Sep;50(9):696-702 [11012982.001]
  • [Cites] Med Oncol. 2000 May;17(2):111-6 [10871816.001]
  • [Cites] Am J Pathol. 1983 Nov;113(2):207-21 [6605690.001]
  • [Cites] IARC Sci Publ. 1997;(143):i-xxxiv, 1-1240 [9505086.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):736-45 [17454632.001]
  • [Cites] Leuk Lymphoma. 2003 Mar;44(3):451-8 [12688314.001]
  • (PMID = 19350421.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Sandlund JT, Pui CH, Zhou Y, Behm FG, Onciu M, Razzouk BI, Hijiya N, Campana D, Hudson MM, Ribeiro RC: Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia; 2009 Jun;23(6):1127-30
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study.
  • There has been a steady improvement in cure rates for children with advanced-stage lymphoblastic non-Hodgkin's lymphoma.
  • To further improve cure rates whereas minimizing long-term toxicity, we designed a protocol (NHL13) based on a regimen for childhood T-cell acute lymphoblastic leukemia, which features intensive intrathecal chemotherapy for central -nervous system-directed therapy and excludes prophylactic cranial irradiation.
  • From 1992 to 2002, 41 patients with advanced-stage lymphoblastic lymphoma were enrolled on the protocol.
  • Thirty patients had stage III and 11 had stage IV disease.
  • Thirty-three cases had a precursor T-cell immunophenotype, five had precursor B-cell immunophenotype and in three immunophenotype was not determined.
  • The treatment described here produces high cure rates in children with lymphoblastic lymphoma without the use of prophylactic cranial irradiation.

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1340-6 [12663724.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):161-80; discussion 200-2 [12196214.001]
  • [Cites] Blood. 2002 Jul 1;100(1):52-8 [12070008.001]
  • [Cites] Blood. 2002 Jul 1;100(1):43-7 [12070006.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2286-94 [11187920.001]
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3616-22 [14512392.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):491-9 [16421426.001]
  • [Cites] Leukemia. 1999 Mar;13(3):335-42 [10086723.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1717-26 [9351539.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1368-76 [7751881.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1024-32 [8501488.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):105-13 [1734214.001]
  • [Cites] Med Pediatr Oncol. 1990;18(4):273-9 [2355886.001]
  • [Cites] Blood. 1985 Nov;66(5):1110-4 [3840395.001]
  • [Cites] J Clin Oncol. 1983 Sep;1(9):537-41 [6689428.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):332-9 [7414342.001]
  • [Cites] Cancer. 1980 Feb 15;45(4):630-7 [6986967.001]
  • (PMID = 19194463.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / P30 CA021765-31
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ NIHMS161582; NLM/ PMC2843413
  •  go-up   go-down


92. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, Fayad L, Wayne Saville M, Kwak LW: Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol; 2009 Apr;20(4):709-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
  • BACKGROUND: To determine the efficacy and side-effects of (90)Y ibritumomab tiuxetan (Zevalin) as front-line treatment in patients with early-stage extranodal indolent lymphoma of the ocular adnexa (orbit, conjunctiva, or eyelid).
  • PATIENTS AND METHODS: From August 2004 to November 2007, 12 patients with stages I-E extranodal indolent lymphoma of the ocular adnexa were enrolled in a prospective trial of rituximab followed by (90)Y ibritumomab tiuxetan (Zevalin therapeutic regimen).
  • Nine patients had mucosa-associated lymphoid tissue lymphoma of conjunctiva or orbit; three patients had grades 1-2 follicular lymphoma of orbit.
  • One patient who had been deemed stage I-E initially was found to have another lesion in her deltoid muscle on positron emission tomography 2 weeks after enrollment.
  • She was kept on trial although her disease was reclassified as stage IV due to this single additional (biopsy-proven) site.
  • There were no episodes of grade III or IV myelosuppression.
  • CONCLUSIONS: Rituximab followed by (90)Y ibritumomab tiuxetan is an effective and safe front-line treatment for early-stage extranodal indolent B-cell lymphoma of the ocular adnexa.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19150940.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


93. Aguiar Bujanda D, Aguiar Morales J, Bohn Sarmiento U, Saura Grau S, Rodríguez Franco C: Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma. Clin Transl Oncol; 2009 Sep;11(9):604-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma.
  • BACKGROUND: The results of CHOP-21 (cyclophosphamide, doxorubicin, vincristine and prednisone given every 21 days) for the treatment of aggressive B-cell lymphoma have recently been improved by the addition of rituximab and by increasing the dose density.
  • PATIENTS AND METHODS: We present our experience with R-CHOP-14 in a retrospective single-centre review of 50 patients consecutively treated for aggressive B-cell lymphoma.
  • Stage III-IV was present in 62% of the patients and international prognostic index was high-to-intermediate risk or high risk in 32% of the patients.
  • CONCLUSIONS: In our experience the combination of RCHOP- 14 is highly effective in patients with aggressive B-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1281-8 [6387060.001]
  • [Cites] Acta Haematol. 2006;115(1-2):22-7 [16424645.001]
  • [Cites] Hematol Oncol. 2008 Mar;26(1):27-32 [17868190.001]
  • [Cites] Leuk Lymphoma. 2005 Apr;46(4):541-7 [16019482.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] N Engl J Med. 1992 Nov 5;327(19):1342-9 [1383819.001]
  • [Cites] Haematologica. 2006 Apr;91(4):496-502 [16537117.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] Lancet Oncol. 2008 Feb;9(2):105-16 [18226581.001]
  • (PMID = 19776000.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


94. Chen CQ, Yin L, Peng CH, Ye M, Zhao R, Chen GM, Zhou HJ, Li HW, Fan YZ: [Primary diffuse large B-cell non-Hodgkin's lymphoma of the small intestine: clinicopathologic features, management, and prognosis in 24 patients]. Zhonghua Zhong Liu Za Zhi; 2007 Sep;29(9):693-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary diffuse large B-cell non-Hodgkin's lymphoma of the small intestine: clinicopathologic features, management, and prognosis in 24 patients].
  • OBJECTIVE: To investigate the clinicopathological features of primary diffuse large B-cell lymphomas (DLBCLs) of the small intestine, CD10 expression, and their relationship to prognosis.
  • All cases were staged according to the Ann Arbor classification of lymphoma.
  • RESULTS: Fifteen cases (62.5%) were at stages I and II, and nine cases (37.5%) at stages III and IV.
  • Although there was no statistically significant difference(P = 0.28) in therapy result between the CD10+ and CDO1--groups, patients with CD10+ lymphoma more frequently presented with stages I compared with those with CD10 - lymphoma (P = 0.013).
  • The analysis of survival rate showed a longer overall survival duration in the stage I and II group compared with that of the stage III and IV group ( P = 0.0197 ) , but there was no significant difference between CD10+ and CD1- groups.
  • CONCLUSION: The primary small intestnal diffuse large B cell lymphoma patients at stage I and II respond better to therapy including surgical resection and chemotherapy than those at stage III and IV.
  • CD10+ expression is more common in stage I lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms. Intestine, Small / surgery. Lymphoma, Large B-Cell, Diffuse. Neprilysin / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246801.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.24.11 / Neprilysin; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


95. Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, Suzumiya J, Okamura T, Nakamura S, Kawa K, Oshimi K: Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci; 2008 May;99(5):1016-20
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
  • Extranodal natural killer (NK)/T-cell lymphoma, nasal type, and aggressive NK-cell leukemia are rare, and their standard therapy has not been established.
  • Patients with stage IV, relapsed or refractory diseases have a dismal prognosis, with survival measured in months only.
  • Eligible patients had newly diagnosed stage IV, relapsed or refractory diseases after first-line chemotherapy, were 15-69 years of age, and had satisfactory performance scores (0-2).
  • At level 1, six patients with extranodal NK/T-cell lymphoma, nasal type, were enrolled.
  • Their disease status was newly diagnosed stage IV (n = 3), first relapse (n = 2), and primary refractory (n = 1).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphoid / drug therapy. Lymphoma, Extranodal NK-T-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294294.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; EC 3.5.1.1 / Asparaginase; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


96. Lee MY, Tsou MH, Tan TD, Lu MC: Clinicopathological analysis of T-cell lymphoma in Taiwan according to WHO classification: high incidence of enteropathy-type intestinal T-cell lymphoma. Eur J Haematol; 2005 Sep;75(3):221-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological analysis of T-cell lymphoma in Taiwan according to WHO classification: high incidence of enteropathy-type intestinal T-cell lymphoma.
  • OBJECTIVES: The clinicopathological characteristics of malignant lymphomas vary according to geography, especially for the T-cell lymphoma (TCL).
  • The incidence of TCL in malignant lymphoma was 12.3%.
  • The most prevalent histologic subtype was peripheral T-cell lymphoma (PTCL), followed by nasal T-cell/Natural killer- (T-/NK-) cell lymphoma, T-lymphoblastic lymphoma (LBL), anaplastic large cell lymphoma, and enteropathy-type intestinal lymphoma (ETCL).
  • Clinically, 39 cases (49%) had higher clinical stage (III/IV).
  • The most common histological subtypes are PTCL, unspecified and T-/NK-cell lymphoma.
  • The clinical stage and histological subtypes are prognostic parameters in determining the survival rates.
  • [MeSH-major] Intestinal Neoplasms / pathology. Lymphoma, T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2005.
  • (PMID = 16104878.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


97. Kim KM, Kim HC, Jeon KN, Kim HG, Kang JH, Hahm JR, Lee GW: Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma. Yonsei Med J; 2008 Feb 29;49(1):155-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.
  • A 69-year-old male was diagnosed in February 2004 with stage IV extranodal marginal zone B cell lymphoma involving the mediastinal nodes, lung parenchyma and bone marrow with high LDH.
  • The patient was well on routine follow-up at the outpatient clinic, with no progression of lymphoma or interstitial pneumonitis.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Diseases, Interstitial / chemically induced. Lung Diseases, Interstitial / pathology. Lymphoma, B-Cell, Marginal Zone / drug therapy

  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1997 Feb;8(2):191-4 [9093730.001]
  • [Cites] Acta Derm Venereol. 2001 Jun-Jul;81(3):207-8 [11558880.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):2-9 [11842383.001]
  • [Cites] Leuk Lymphoma. 2001 Nov-Dec;42(6):1329-37 [11911416.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2690-1; discussion 2690-1 [12826649.001]
  • [Cites] Clin Lymphoma. 2003 Jun;4(1):36-42 [12837153.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2741-5 [12842999.001]
  • [Cites] Eur J Cancer. 2004 Jun;40(9):1320-6 [15177490.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2321-5 [15512824.001]
  • [Cites] Cytometry. 1993;14(2):196-204 [7679964.001]
  • [Cites] Cytometry. 1994 Jun 15;18(2):88-92 [7523045.001]
  • [Cites] Am J Clin Pathol. 1996 Jul;106(1):78-81 [8701937.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1916-21 [9586910.001]
  • [Cites] Ann Hematol. 1998 Jul-Aug;77(1-2):89-91 [9760161.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):791-5 [10071268.001]
  • [Cites] Am J Hematol. 2005 Apr;78(4):275-80 [15795920.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6387-93 [16155024.001]
  • [Cites] J Rheumatol. 2005 Nov;32(11):2109-15 [16265687.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:307-13 [16304396.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Mar;6(5):407-9 [16640819.001]
  • [Cites] Korean J Intern Med. 2006 Sep;21(3):183-6 [17017668.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1258-64 [11483337.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1619-26 [11587221.001]
  • (PMID = 18306483.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Other-IDs] NLM/ PMC2615269
  •  go-up   go-down


98. Nguyen XC, Lee WW, Amin AM, Eo JS, Bang SM, Lee JS, Kim SE: Tumor Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-cell Lymphoma. Nucl Med Mol Imaging; 2010 Apr;44(1):39-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-cell Lymphoma.
  • PURPOSE: It is uncertain whether the tumor burden as assessed using FDG-PET has prognostic significance in newly diagnosed diffuse large B-cell lymphoma (DLBCL).
  • MATERIALS AND METHODS: Forty-two DLBCL patients (age, 57.4 ± 15.5 years; male/female = 25/17; stage I/II/III/IV=5/17/10/10) who underwent FDG-PET before chemotherapy were enrolled.
  • Among six variables [Ann Arbor stage, %Ki-67 expression, International Prognostic Index (IPI), MaxSUV, greatest diameter, and SIMaxSUV] investigated, only SIMaxSUV was found to be a single determinant of progression-free and overall survivals by multivariate analyses (p < 0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24899936.001).
  • [ISSN] 1869-3474
  • [Journal-full-title] Nuclear medicine and molecular imaging
  • [ISO-abbreviation] Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC4042962
  • [Keywords] NOTNLM ; FDG-PET / Greatest diameter / Lymphoma / Prognosis / SUV / Size-incorporated maxSUV
  •  go-up   go-down


99. Lim ST, Hee SW, Quek R, Lim LC, Yap SP, Loong EL, Sng I, Tan LH, Ang MK, Ngeow J, Tham CK, Ngo L, Tan MH, Tao M: Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis. Eur J Haematol; 2008 Jan;80(1):55-60
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis.
  • AIM: We aimed to compare the frequencies, clinical characteristics, and prognostic factors of peripheral T-cell lymphoma (PTCL) vs. extra-nodal natural killer (NK)/T-cell lymphoma and to characterize the subtypes of extra-nodal NK/T-cell lymphoma.
  • METHODS: We reviewed 97 consecutive patients with PTCL and extra-nodal NKT lymphoma from 2000 to 2006.
  • RESULTS: Extra-nodal-NK/T-cell lymphoma and PTCL comprised 5.0% (39/780) and 7.4% (58/780) of all cases.
  • Of the PTCL cases, histology was PTCL-NOS in 25, anaplastic large cell in 11, angioimmunoblastic T cell in 18 and other subtypes in four patients.
  • Compared with PTCL, extra-nodal NK/T-cell lymphoma was associated with a significantly inferior rates of complete remission (33% vs. 53%, P = 0.05) and 3 yr overall survival (29.5% vs. 47.5%, P = 0.003).
  • On multivariate analysis, extra-nodal NK/T-cell histology was independently associated with decreased survival.
  • Further analysis into this subtype showed the nasal variant (n = 25) differed significantly from extra-nasal variant (n = 14) in terms of stage at presentation (stages III/IV, 36% vs. 79%), international prognostic index scores (high intermediate or high IPI scores, 24% vs. 64%), complete remission rates (48% vs. 7%), and median survival (10 months vs. 1 month, P < 0.0001).
  • CONCLUSIONS: Extra-nodal NK/T-cell lymphoma was associated with a poorer prognosis compared with PTCL and is likely to comprise two distinct variants with different clinical behavior and prognosis.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell, Peripheral / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18028433.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


100. Wada N, Kohara M, Ikeda J, Hori Y, Fujita S, Okada M, Ogawa H, Sugiyama H, Fukuhara S, Kanamaru A, Hino M, Kanakura Y, Morii E, Aozasa K: Diffuse large B-cell lymphoma in the spinal epidural space: A study of the Osaka Lymphoma Study Group. Pathol Res Pract; 2010 Jul 15;206(7):439-44
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma in the spinal epidural space: A study of the Osaka Lymphoma Study Group.
  • Diffuse large B-cell lymphoma (DLBCL) involving spinal epidural space (SEDLBCL) is relatively rare, constituting 1.8% of DLBCLs in Osaka, Japan.
  • Eight patients had stage I disease, 3 had stage II, 5 had stage III, and 11 had stage IV.
  • Based on the staining pattern for anti-CD10, bcl-6, and MUM-1, the cases were categorized into 17 cases of the germinal center B-cell (GCB) type and nine of the non-GCB type.
  • There was a 4%-positive rate for EBV in the tumor cells.
  • Compared to the DLBCL of the central nervous system (CNS), the frequency of cases with high stage, 2 or more extranodal lesions, high international prognostic index (IPI), and GCB-type is higher in SEDLBCL.
  • Univariate analysis revealed that advanced stage was an unfavorable factor for overall survival (P=0.060).
  • [MeSH-major] Epidural Space / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20399024.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement